Date,Open,High,Low,Close,Volume,Dividends,Stock Splits,SMA_10,SMA_40,SMA_120,Close_10_%_D,10_40_%_D,40_120_%_D,RSI,earningsGrowth,revenueGrowth,profitMargins,grossMargins,returnOnEquity,debtToEquity,priceToBook,forwardPE,longName,sector,longBusinessSummary
2022-06-27,3.9800000190734863,3.9800000190734863,3.3550000190734863,3.799999952316284,4516,0.0,0.0,,,,,,,,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-06-28,4.0,4.0,3.5999999046325684,3.7950000762939453,19457,0.0,0.0,,,,,,,0.0,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-06-29,3.7899999618530273,3.7950000762939453,3.6449999809265137,3.7899999618530273,2091,0.0,0.0,,,,,,,0.0,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-06-30,3.7899999618530273,3.7899999618530273,3.5,3.75,6617,0.0,0.0,,,,,,,0.0,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-07-01,3.359999895095825,3.75,3.359999895095825,3.75,2396,0.0,0.0,,,,,,,0.0,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-07-04,3.640000104904175,3.700000047683716,3.640000104904175,3.700000047683716,1526,0.0,0.0,,,,,,,0.0,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-07-05,3.75,3.75,3.4549999237060547,3.5999999046325684,59163,0.0,0.0,,,,,,,0.0,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-07-06,3.5950000286102295,3.694999933242798,3.4000000953674316,3.549999952316284,8608,0.0,0.0,,,,,,,0.0,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-07-07,3.4000000953674316,3.694999933242798,3.3949999809265137,3.5999999046325684,28716,0.0,0.0,,,,,,,19.49453890228763,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-07-08,3.694999933242798,3.694999933242798,3.4749999046325684,3.625,2289,0.0,0.0,3.6959999799728394,,,-1.920995139544376,,,27.142473238381186,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-07-11,3.694999933242798,3.694999933242798,3.4200000762939453,3.4200000762939453,26057,0.0,0.0,3.6579999923706055,,,-6.506285308175242,,,14.76008549850043,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-07-12,3.4200000762939453,3.4200000762939453,3.380000114440918,3.4000000953674316,24602,0.0,0.0,3.618499994277954,,,-6.038410923201412,,,14.084979798397029,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-07-13,3.3499999046325684,3.5950000286102295,3.3499999046325684,3.484999895095825,64089,0.0,0.0,3.5879999876022337,,,-2.8706826327287915,,,28.9572047816511,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-07-14,3.450000047683716,3.734999895095825,3.4049999713897705,3.5850000381469727,5917,0.0,0.0,3.571499991416931,,,0.3779937494745946,,,41.73562931191861,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-07-15,3.5799999237060547,3.5799999237060547,3.4000000953674316,3.494999885559082,8983,0.0,0.0,3.5459999799728394,,,-1.4382429413930242,,,35.539798613824885,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-07-18,3.494999885559082,3.494999885559082,3.299999952316284,3.490000009536743,55560,0.0,0.0,3.524999976158142,,,-0.9929068612234431,,,35.22692568179379,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-07-19,3.384999990463257,3.569999933242798,3.384999990463257,3.5199999809265137,3318,0.0,0.0,3.5169999837875365,,,0.0852998906114971,,,38.713235752129435,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-07-20,3.5199999809265137,3.5999999046325684,3.5199999809265137,3.549999952316284,3351,0.0,0.0,3.5169999837875365,,,0.9382987967264429,,,42.071014720285106,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-07-21,3.494999885559082,3.6050000190734863,3.494999885559082,3.5950000286102295,16201,0.0,0.0,3.5164999961853027,,,2.2323342104388897,,,46.78109629536535,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-07-22,3.5,3.549999952316284,3.484999895095825,3.5,8009,0.0,0.0,3.5039999961853026,,,-0.11415514239889356,,,39.48259958703143,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-07-25,3.5,3.5,3.4000000953674316,3.484999895095825,20901,0.0,0.0,3.5104999780654906,,,-0.7263946198261368,,,38.46224094034119,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-07-26,3.484999895095825,3.5799999237060547,3.484999895095825,3.5450000762939453,5647,0.0,0.0,3.524999976158142,,,0.5673787310943789,,,44.62664242631587,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-07-27,3.5450000762939453,3.5450000762939453,3.5299999713897705,3.5299999713897705,2375,0.0,0.0,3.5294999837875367,,,0.014165961312663242,,,43.454683875604,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-07-28,3.6449999809265137,3.6449999809265137,3.5,3.640000104904175,9561,0.0,0.0,3.5349999904632567,,,2.970300275083111,,,53.16757062846946,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-07-29,3.625,3.625,3.6050000190734863,3.6050000190734863,3502,0.0,0.0,3.5460000038146973,,,1.6638470162244314,,,50.21213851912757,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-08-01,3.5999999046325684,3.6050000190734863,3.4000000953674316,3.5,29999,0.0,0.0,3.547000002861023,,,-1.3250635134793558,,,42.567495328911086,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-08-02,3.5,3.994999885559082,3.4049999713897705,3.940000057220459,50177,0.0,0.0,3.5890000104904174,,,9.77988424920844,,,65.95710662404073,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-08-03,3.940000057220459,4.400000095367432,3.700000047683716,4.28000020980835,86166,0.0,0.0,3.662000036239624,,,16.876028603301915,,,74.57405384935517,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-08-04,4.269999980926514,4.28000020980835,3.8350000381469727,4.28000020980835,33537,0.0,0.0,3.730500054359436,,,14.72993291627945,,,74.57405384935515,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-08-05,4.28000020980835,4.28000020980835,3.9049999713897705,4.28000020980835,15313,0.0,0.0,3.808500075340271,,,12.380205465164721,,,74.57405384935515,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-08-08,4.28000020980835,4.860000133514404,4.0,4.494999885559082,93877,0.0,0.0,3.909500074386597,,,14.976334570459127,,,78.81016450947574,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-08-09,4.25,4.5,4.15500020980835,4.489999771118164,13339,0.0,0.0,4.004000043869018,,,12.137855192916783,,,78.48267995537167,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-08-10,4.480000019073486,5.489999771118164,4.199999809265137,4.744999885559082,24326,0.0,0.0,4.12550003528595,,,15.016357895393712,,,82.48089101209925,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-08-11,4.744999885559082,4.744999885559082,4.329999923706055,4.684999942779541,22390,0.0,0.0,4.230000019073486,,,10.756499329891614,,,78.77199607488302,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-08-12,4.349999904632568,4.664999961853027,4.25,4.375,21332,0.0,0.0,4.307000017166137,,,1.5788247634743309,,,63.00753473947083,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-08-15,4.315000057220459,4.75,4.315000057220459,4.590000152587891,4503,0.0,0.0,4.416000032424927,,,3.9402200834544843,,,67.81795250147151,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-08-16,4.945000171661377,4.945000171661377,4.460000038146973,4.5,4167,0.0,0.0,4.472000026702881,,,0.6261174671271775,,,64.0624976305868,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-08-17,4.5,4.985000133514404,4.5,4.760000228881836,5967,0.0,0.0,4.520000028610229,,,5.309738910453056,,,69.34390715438622,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-08-18,4.574999809265137,4.664999961853027,4.460000038146973,4.585000038146973,12677,0.0,0.0,4.550500011444091,,,0.7581590290323437,,,62.66818093515497,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-08-19,4.554999828338623,4.744999885559082,4.244999885559082,4.550000190734863,20152,0.0,0.0,4.5775000095367435,3.896500015258789,,-0.6007606497998303,17.47722293368772,,61.39515680891132,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-08-22,4.400000095367432,4.550000190734863,4.300000190734863,4.550000190734863,20430,0.0,0.0,4.583000040054321,3.9152500212192534,,-0.7200490733372656,17.055105426629247,,61.39515680891132,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-08-23,4.5,4.75,4.5,4.599999904632568,8243,0.0,0.0,4.594000053405762,3.9353750169277193,,0.13060189719324172,16.73601711768298,,62.65213029177932,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-08-24,4.599999904632568,4.639999866485596,4.40500020980835,4.614999771118164,9137,0.0,0.0,4.58100004196167,3.9560000121593477,,0.7421901079471425,15.798787357969992,,63.04091581206045,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-08-25,4.934999942779541,4.934999942779541,4.505000114440918,4.855000019073486,22337,0.0,0.0,4.5980000495910645,3.9836250126361845,,5.589385965867462,15.422511782762255,,68.6620484375253,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-08-26,4.849999904632568,4.949999809265137,4.715000152587891,4.880000114440918,17915,0.0,0.0,4.648500061035156,4.011875015497208,,4.980102191376766,15.868516418850815,,69.18775170714437,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-08-29,4.934999942779541,4.934999942779541,4.559999942779541,4.690000057220459,4689,0.0,0.0,4.658500051498413,4.036625015735626,,0.6761834361666312,15.405816327713994,,60.835156197383036,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-08-30,4.900000095367432,4.900000095367432,4.5,4.659999847412109,19869,0.0,0.0,4.674500036239624,4.063125014305115,,-0.31019764071237593,15.046916345965986,,59.611449994142056,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-08-31,4.5,4.900000095367432,4.40500020980835,4.900000095367432,8395,0.0,0.0,4.688500022888183,4.096875017881393,,4.5110391691746505,14.440884879928209,,65.57691620248136,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-09-01,4.465000152587891,4.835000038146973,4.460000038146973,4.695000171661377,7583,0.0,0.0,4.699500036239624,4.124250024557114,,-0.09575198518027637,13.94799074394827,,57.73293638578861,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-09-02,4.875,4.875,4.349999904632568,4.534999847412109,11067,0.0,0.0,4.6980000019073485,4.147000020742416,,-3.4695648026620347,13.286712766070586,,52.458752328999815,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-09-05,4.300000190734863,4.489999771118164,4.199999809265137,4.199999809265137,9757,0.0,0.0,4.662999963760376,4.166500014066696,,-9.929233499754575,11.916475411434654,,43.49859661055102,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-09-06,4.340000152587891,4.965000152587891,4.0,4.46999979019165,51868,0.0,0.0,4.649999952316284,4.193250006437301,,-3.870971268181858,10.89250450552195,,50.793559847061864,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-09-07,4.300000190734863,4.454999923706055,4.099999904632568,4.355000019073486,18744,0.0,0.0,4.623999977111817,4.215000009536743,,-5.81747316976307,9.703439303669796,,47.953656704373955,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-09-08,4.355000019073486,4.355000019073486,4.355000019073486,4.355000019073486,11,0.0,0.0,4.573999977111816,4.234250009059906,,-4.787930894932229,8.023852330990296,,47.95365670437396,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-09-09,4.474999904632568,4.474999904632568,4.414999961853027,4.414999961853027,931,0.0,0.0,4.527499961853027,4.257250010967255,,-2.4848150402624305,6.34799342743724,,49.65682933076931,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-09-12,4.199999809265137,4.40500020980835,4.114999771118164,4.34499979019165,2433,0.0,0.0,4.492999935150147,4.278625005483628,,-3.2940161828324306,5.010369672307555,,47.69581107317931,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-09-13,4.349999904632568,4.349999904632568,4.175000190734863,4.34499979019165,1688,0.0,0.0,4.461499929428101,4.299250000715256,,-2.6112325692983664,3.7739123960191043,,47.69581107317931,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-09-14,4.34499979019165,4.34499979019165,4.050000190734863,4.199999809265137,9938,0.0,0.0,4.3914999008178714,4.315499997138977,,-4.360698983895453,1.7610915010839994,,43.56288626149597,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-09-15,4.335000038146973,4.335000038146973,4.199999809265137,4.289999961853027,3588,0.0,0.0,4.350999879837036,4.332874995470047,,-1.401974710840335,0.41831080716471314,,46.6528169781041,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-09-16,4.199999809265137,4.28000020980835,4.199999809265137,4.199999809265137,821,0.0,0.0,4.317499876022339,4.350374990701676,,-2.7214839636649524,-0.7556846191329003,,44.05525256903054,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-09-19,4.25,4.25,4.0,4.144999980926514,23507,0.0,0.0,4.311999893188476,4.366874992847443,,-3.8729108626780526,-1.2566217203113672,,42.497997715087045,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-09-20,4.195000171661377,4.199999809265137,4.0,4.090000152587891,1292,0.0,0.0,4.273999929428101,4.380499994754791,,-4.305095458081366,-2.4312308059402685,,40.93955860992037,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-09-21,4.25,4.25,3.5,3.8949999809265137,13515,0.0,0.0,4.227999925613403,4.38962499499321,,-7.876063163330771,-3.681978974608438,,35.91136873004963,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-09-22,4.0,4.0,3.694999933242798,3.694999933242798,2715,0.0,0.0,4.161999917030334,4.390999990701675,,-11.220566869226408,-5.215214624374146,,31.621615098206846,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-09-23,3.700000047683716,3.700000047683716,3.609999895095825,3.700000047683716,6617,0.0,0.0,4.090499925613403,4.393374991416931,,-9.546507395942044,-6.893904262559802,,31.84082453640879,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-09-26,3.700000047683716,4.199999809265137,3.700000047683716,4.114999771118164,3548,0.0,0.0,4.0674999237060545,4.408749985694885,,1.1677897554532866,-7.740290628774324,,47.021541260017926,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-09-27,3.9600000381469727,4.034999847412109,3.75,3.9200000762939453,4495,0.0,0.0,4.024999952316284,4.408249986171723,,-2.6086926028884494,-8.69392695644891,,42.25881056781256,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-09-28,3.6500000953674316,3.869999885559082,3.549999952316284,3.865000009536743,8578,0.0,0.0,3.991499972343445,4.397874981164932,,-3.169233713721726,-9.240258319345052,,40.99747612555943,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-09-29,4.085000038146973,4.09499979019165,3.755000114440918,4.070000171661377,3536,0.0,0.0,3.9694999933242796,4.392624980211258,,2.531809510167877,-9.632622607055072,,47.31017941149063,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-09-30,4.070000171661377,4.070000171661377,3.5999999046325684,4.014999866485596,3778,0.0,0.0,3.9509999990463256,4.385999971628189,,1.619839722974389,-9.917920095662502,,45.89153690611861,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-10-03,4.010000228881836,4.010000228881836,3.75,4.005000114440918,6160,0.0,0.0,3.937000012397766,4.373749977350235,,1.7272060408691083,-9.985709453311419,,45.62367101531418,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-10-04,4.0,4.0,3.6500000953674316,3.799999952316284,12214,0.0,0.0,3.9079999923706055,4.356499981880188,,-2.7635629545845553,-10.294961353724556,,40.41552985826949,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-10-05,3.994999885559082,3.994999885559082,3.625,3.744999885559082,23591,0.0,0.0,3.8929999828338624,4.331499981880188,,-3.801697866102878,-10.123513814629739,,39.12507908154664,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-10-06,3.994999885559082,3.994999885559082,3.6500000953674316,3.9000000953674316,6726,0.0,0.0,3.9134999990463255,4.311874985694885,,-0.34495729352711474,-9.239019868855477,,44.503022743863056,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-10-07,3.890000104904175,4.144999980926514,3.625,3.8299999237060547,48557,0.0,0.0,3.9264999866485595,4.298249983787537,,-2.457661104562281,-8.648868691704115,,42.66965950892266,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-10-10,3.6649999618530273,3.8299999237060547,3.6500000953674316,3.8299999237060547,5494,0.0,0.0,3.8980000019073486,4.279249978065491,,-1.7444863562858004,-8.909270973005716,,42.669659508922656,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-10-11,3.994999885559082,3.994999885559082,3.684999942779541,3.7899999618530273,2471,0.0,0.0,3.884999990463257,4.261499977111816,,-2.445303187733122,-8.83491701679482,,41.535667381251386,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-10-12,3.799999952316284,4.199999809265137,3.700000047683716,3.7300000190734863,7476,0.0,0.0,3.8714999914169312,4.235749971866608,,-3.654913409715838,-8.59942118559843,,39.82591745376374,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-10-13,3.700000047683716,3.8949999809265137,3.615000009536743,3.684999942779541,3108,0.0,0.0,3.8329999685287475,4.213249969482422,,-3.861206025681616,-9.025099476838925,,38.544413529730264,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-10-14,3.680000066757202,3.684999942779541,3.5299999713897705,3.684999942779541,22595,0.0,0.0,3.799999976158142,4.191624963283539,,-3.0263166868455555,-9.343034993727468,,38.544413529730264,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-10-17,3.5999999046325684,3.740000009536743,3.5999999046325684,3.740000009536743,7469,0.0,0.0,3.7734999656677246,4.171374958753586,,-0.8877688203464339,-9.538221737917013,,41.22521429455593,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-10-18,3.6050000190734863,4.985000133514404,3.565000057220459,4.5,65708,0.0,0.0,3.8434999704360964,4.168874961137772,,17.080786642738413,-7.804863272101446,,64.36033720448789,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-10-19,4.5,4.5,4.0,4.079999923706055,12547,0.0,0.0,3.8769999742507935,4.155499964952469,,5.236005953146536,-6.701961088931471,,52.144807795885,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-10-20,4.190000057220459,4.635000228881836,3.819999933242798,4.300000190734863,2279,0.0,0.0,3.9169999837875364,4.1416249692440035,,9.77789656708105,-5.423595499943811,,56.772963559428106,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-10-21,4.300000190734863,4.489999771118164,3.924999952316284,3.934999942779541,10013,0.0,0.0,3.9274999856948853,4.117999964952469,,0.19096007923546102,-4.626031590065414,,48.408219679917664,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-10-24,3.950000047683716,4.300000190734863,3.950000047683716,4.099999904632568,3049,0.0,0.0,3.9544999837875365,4.103249961137772,,3.6793506496787254,-3.6251746483655407,,51.861108064253834,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-10-25,4.09499979019165,4.09499979019165,3.8499999046325684,4.065000057220459,18151,0.0,0.0,3.98199999332428,4.088374966382981,,2.0843813168088063,-2.6018888661969215,,51.0801615729013,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-10-26,4.059999942779541,4.059999942779541,3.825000047683716,3.984999895095825,4448,0.0,0.0,4.0074999809265135,4.06549996137619,,-0.5614494307617288,-1.4266383224867487,,49.25444111741044,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-10-27,3.984999895095825,4.0,3.8499999046325684,3.994999885559082,6995,0.0,0.0,4.038499975204468,4.0479999542236325,,-1.077134825119906,-0.23468327881901704,,49.49743139017059,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-10-28,3.859999895095825,4.0,3.825000047683716,4.0,13578,0.0,0.0,4.0699999809265135,4.03462495803833,,-1.7199012593257648,0.8767859034258961,,49.627313997937804,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-10-31,4.199999809265137,5.190000057220459,3.8550000190734863,4.244999885559082,5521,0.0,0.0,4.120499968528748,4.0357499599456785,,3.0214759854685305,2.0999816496116566,,55.64647907476663,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-11-01,4.239999771118164,4.59499979019165,4.014999866485596,4.114999771118164,7323,0.0,0.0,4.081999945640564,4.0268749594688416,,0.808422976899913,1.368927188615596,,52.08971037021781,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-11-02,4.099999904632568,4.199999809265137,3.890000104904175,4.150000095367432,14514,0.0,0.0,4.088999962806701,4.02174996137619,,1.4918105433011466,1.6721576944455103,,52.961446228614854,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-11-03,4.0,4.0,3.8350000381469727,3.9600000381469727,9421,0.0,0.0,4.054999947547913,4.011874961853027,,-2.3427844791560863,1.0749334439617386,,47.86952602327825,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-11-04,3.9000000953674316,4.175000190734863,3.7049999237060547,4.175000190734863,11026,0.0,0.0,4.0789999723434445,4.005874967575073,,2.353523389122881,1.8254440131125027,,53.33674538266022,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-11-07,4.0,4.0,3.75,3.799999952316284,13204,0.0,0.0,4.048999977111817,3.992249971628189,,-6.14966723149122,1.4215043117774167,,44.55891993851085,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-11-08,3.934999942779541,4.085000038146973,3.934999942779541,4.0,1608,0.0,0.0,4.042499971389771,3.983624976873398,,-1.0513289224627904,1.4779251274446399,,49.34687344752913,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-11-09,4.164999961853027,4.164999961853027,3.805000066757202,3.9749999046325684,1750,0.0,0.0,4.041499972343445,3.9779999792575835,,-1.6454303641208912,1.5962793719700406,,48.77978038719723,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-11-10,3.799999952316284,4.085000038146973,3.799999952316284,3.9800000190734863,3436,0.0,0.0,4.039999985694886,3.970249980688095,,-1.4851476939072117,1.7568164560434543,,48.90624978020719,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-11-11,3.799999952316284,3.990000009536743,3.799999952316284,3.9000000953674316,921,0.0,0.0,4.029999995231629,3.9627499878406525,,-3.2258039706703587,1.6970540053580723,,46.91048994335942,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-11-14,4.139999866485596,4.139999866485596,4.105000019073486,4.105000019073486,608,0.0,0.0,4.0160000085830685,3.9617499887943266,,2.2161357146465486,1.3693448587666106,,52.28398544098662,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-11-15,4.09499979019165,4.394999980926514,3.9000000953674316,4.0,60266,0.0,0.0,4.004500031471252,3.9594999849796295,,-0.11237436473684158,1.136508313229718,,49.51931624763529,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-11-16,4.489999771118164,4.489999771118164,3.9000000953674316,4.114999771118164,5494,0.0,0.0,4.000999999046326,3.964999979734421,,2.8492819819797814,0.9079450062018993,,52.48289673658887,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-11-17,4.59499979019165,4.59499979019165,3.9149999618530273,4.0,11351,0.0,0.0,4.004999995231628,3.9726249814033507,,-0.12484382615683984,0.8149526819126288,,49.36207076291366,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-11-18,4.0,4.425000190734863,4.0,4.099999904632568,14693,0.0,0.0,3.997499966621399,3.982624977827072,,2.5641010348225284,0.3734970999564844,,52.03311198721588,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-11-21,3.9000000953674316,4.235000133514404,3.8550000190734863,4.105000019073486,19222,0.0,0.0,4.027999973297119,3.982374984025955,,1.911619818441537,1.1456728573821917,,52.16896818161032,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-11-22,4.110000133514404,4.195000171661377,3.865000009536743,4.135000228881836,11340,0.0,0.0,4.041499996185303,3.9877499878406524,,2.3135032236740316,1.3478780893622693,,53.028576587608875,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-11-23,4.0,4.144999980926514,3.9000000953674316,4.139999866485596,20359,0.0,0.0,4.057999992370606,3.994624984264374,,2.0206967537988367,1.5865070777827377,,53.179593297106315,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-11-24,4.139999866485596,4.170000076293945,3.9000000953674316,4.114999771118164,31213,0.0,0.0,4.071499967575074,3.9957499742507934,,1.0683974920672372,1.8957640946611887,,52.27454989433748,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-11-25,4.114999771118164,4.139999866485596,4.085000038146973,4.09499979019165,4488,0.0,0.0,4.090999937057495,3.9977499723434446,,0.09777201651664105,2.33256119965371,,51.519169260616074,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-11-28,4.090000152587891,4.199999809265137,4.0,4.0,12058,0.0,0.0,4.080499935150146,3.997624969482422,,-1.972795893383202,2.073105063641182,,47.97307063881038,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-11-29,4.474999904632568,4.474999904632568,3.9100000858306885,4.144999980926514,4620,0.0,0.0,4.094999933242798,4.006249970197677,,1.2210024053436508,2.215287705593214,,53.261062478855884,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-11-30,4.139999866485596,4.144999980926514,3.9549999237060547,4.144999980926514,9619,0.0,0.0,4.097999954223633,4.016249972581863,,1.146901591700595,2.035480415807301,,53.261062478855884,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-12-01,4.159999847412109,4.210000038146973,4.144999980926514,4.170000076293945,1066,0.0,0.0,4.1149999618530275,4.022999972105026,,1.336576305000758,2.2868503700203227,,54.19205560051487,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-12-02,4.210000038146973,4.210000038146973,3.9700000286102295,4.099999904632568,18177,0.0,0.0,4.1149999618530275,4.029749971628189,,-0.3645214425155056,2.1155156231788164,,51.12152412927328,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-12-05,4.050000190734863,4.485000133514404,4.014999866485596,4.449999809265137,48692,0.0,0.0,4.149499940872192,4.045249968767166,,7.241833297382379,2.577095925095511,,62.54788187085094,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-12-06,4.445000171661377,4.445000171661377,4.125,4.25,24049,0.0,0.0,4.160999917984009,4.0567499697208405,,2.138910929349672,2.569789832779428,,54.68146999607098,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-12-07,4.320000171661377,4.59499979019165,4.099999904632568,4.59499979019165,63605,0.0,0.0,4.206499910354614,4.078374963998795,,9.23570398470032,3.1415685778483278,,63.2642329783115,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-12-08,4.579999923706055,4.579999923706055,4.360000133514404,4.474999904632568,15418,0.0,0.0,4.242499923706054,4.09812496304512,,5.480258930055858,3.5229516416126025,,59.0734936696075,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-12-09,4.579999923706055,4.579999923706055,4.199999809265137,4.329999923706055,20756,0.0,0.0,4.2659999370574955,4.114249962568283,4.067458313703537,1.5002341207886578,3.6883994864153573,1.1503903729535854,54.38549697472855,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-12-12,4.199999809265137,4.394999980926514,4.034999847412109,4.260000228881836,20615,0.0,0.0,4.291999959945679,4.127249968051911,4.071291649341584,-0.7455669003372528,3.9917619036661254,1.37446106862368,52.23057127092207,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-12-13,4.045000076293945,4.25,4.045000076293945,4.099999904632568,6156,0.0,0.0,4.287499952316284,4.117249965667725,4.073833314577739,-4.373179003358831,4.135041303496585,1.0657444165578551,47.58899849045029,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-12-14,4.099999904632568,4.349999904632568,4.034999847412109,4.099999904632568,26709,0.0,0.0,4.28299994468689,4.117749965190887,4.076416647434234,-4.272707037536508,4.013113493848143,1.0139620488172798,47.58899849045029,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-12-15,4.099999904632568,4.099999904632568,3.700000047683716,3.990000009536743,65392,0.0,0.0,4.26499993801117,4.109999960660934,4.078416647513707,-6.447829600735301,3.7712890227208127,0.7744013394629657,44.440116720929325,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-12-16,3.880000114440918,3.950000047683716,3.7899999618530273,3.944999933242798,7606,0.0,0.0,4.249499940872193,4.110249960422516,4.0800416469573975,-7.165549167342674,3.3878713409284287,0.7403922822122652,43.18133193302267,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-12-19,3.950000047683716,3.950000047683716,3.75,3.8499999046325684,29173,0.0,0.0,4.189499950408935,4.103999960422516,4.081291645765305,-8.103593502685886,2.0833331094286143,0.5564001945504919,40.568788591843145,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-12-20,3.75,3.8949999809265137,3.7049999237060547,3.7750000953674316,30703,0.0,0.0,4.141999959945679,4.09674996137619,4.082749980688095,-8.860450703216815,1.1045340573894347,0.3429056580568706,38.58408010548747,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-12-21,3.950000047683716,3.950000047683716,3.759999990463257,3.8550000190734863,36067,0.0,0.0,4.067999982833863,4.093499964475631,4.085291647911072,-5.235987331838572,-0.6229383623565071,0.20092363708613986,41.851872932563346,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-12-22,3.8550000190734863,3.8550000190734863,3.6700000762939453,3.7850000858306885,35580,0.0,0.0,3.999000000953674,4.088249969482422,4.086833316087723,-5.351335710726465,-2.1830849188521304,0.03466384080609488,39.85369182436861,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-12-23,3.609999895095825,3.7699999809265137,3.609999895095825,3.759999990463257,4208,0.0,0.0,3.9420000076293946,4.082249969244003,4.08795831600825,-4.616946139368157,-3.435604450272842,-0.13963808637415173,39.13504662463426,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-12-27,3.759999990463257,3.759999990463257,3.5,3.680000066757202,28467,0.0,0.0,3.883999991416931,4.068124973773957,4.0901249825954435,-5.2523152706111915,-4.526040461982536,-0.5378810895780132,36.845432873501764,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-12-28,3.549999952316284,3.859999895095825,3.5,3.5999999046325684,60550,0.0,0.0,3.833999991416931,4.055249977111816,4.091791647672653,-6.103288662186027,-5.455890190336952,-0.8930481732035678,34.66154534506002,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-12-29,3.619999885559082,3.634999990463257,3.515000104904175,3.549999952316284,4146,0.0,0.0,3.778999996185303,4.040249973535538,4.092333314816157,-6.059805347980469,-6.466183505017647,-1.2727052581971612,33.33179911657804,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2022-12-30,3.509999990463257,3.5950000286102295,3.450000047683716,3.515000104904175,8372,0.0,0.0,3.731500005722046,4.029124975204468,4.091749982039134,-5.8019536509682625,-7.386838862383962,-1.5305189004597135,32.39492955335787,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-01-02,3.984999895095825,3.984999895095825,3.484999895095825,3.694999933242798,33675,0.0,0.0,3.706500005722046,4.017124968767166,4.0934166491031645,-0.3102677043435738,-7.732519288302077,-1.863765330429128,41.50151589640171,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-01-03,3.6549999713897705,3.6549999713897705,3.434999942779541,3.509999990463257,7292,0.0,0.0,3.6725000143051147,4.0098749697208405,4.093583315610886,-4.424779393026226,-8.413602867004432,-2.0448672821882794,36.11672450839979,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-01-04,3.619999885559082,3.619999885559082,3.450000047683716,3.569999933242798,1468,0.0,0.0,3.651999998092651,3.9991249680519103,4.093999981880188,-2.245346793337348,-8.680023073356313,-2.317416078363193,38.886264731154036,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-01-05,3.450000047683716,3.549999952316284,3.450000047683716,3.549999952316284,8123,0.0,0.0,3.6214999914169312,3.9884999692440033,4.093999981880188,-1.9743211174956345,-9.201453695802202,-2.5769421862022903,38.29036466673922,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-01-09,3.5,3.7899999618530273,3.5,3.680000066757202,17783,0.0,0.0,3.6109999895095823,3.980999970436096,4.094708315531412,1.910830170259592,-9.294146789103904,-2.7769583651176175,44.26863712488521,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-01-10,3.7850000858306885,4.389999866485596,3.7699999809265137,3.934999942779541,70283,0.0,0.0,3.628499984741211,3.981874966621399,4.0983333150545755,8.447015552631731,-8.874587596104877,-2.8416026584608307,53.736322077505925,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-01-11,4.019999980926514,4.144999980926514,3.700000047683716,3.8299999237060547,58046,0.0,0.0,3.643499970436096,3.974999964237213,4.101208315292994,5.118703301310471,-8.33962256059367,-3.0773455370497205,49.971853434938595,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-01-12,3.875,4.0,3.6449999809265137,3.8499999046325684,59410,0.0,0.0,3.668499970436096,3.9712499618530273,4.103749980529149,4.947524483008141,-7.623544081210763,-3.228754658660684,50.680579809274974,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-01-13,3.875,4.0,3.759999990463257,3.8499999046325684,18359,0.0,0.0,3.6984999656677244,3.9646249651908874,4.106416646639506,4.096253626366933,-6.712488617705853,-3.452929735336377,50.680579809274974,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-01-16,3.8499999046325684,4.09499979019165,3.7200000286102295,3.9000000953674316,5509,0.0,0.0,3.7369999647140504,3.962124967575073,4.1085833132267,4.361791067500151,-5.68192585300522,-3.5646921210076408,52.626440070753596,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-01-17,3.9000000953674316,3.9000000953674316,3.6600000858306885,3.7799999713897705,53848,0.0,0.0,3.7454999685287476,3.9541249692440035,4.110041646162669,0.9211054105167896,-5.276135740220252,-3.7935546727181406,47.75652770438859,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-01-18,3.9000000953674316,3.9000000953674316,3.630000114440918,3.7899999618530273,12776,0.0,0.0,3.7734999656677246,3.946249967813492,4.1124583125114444,0.43725974123291245,-4.3775737359456555,-4.0415812652080225,48.18681646762341,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-01-19,3.8350000381469727,3.8350000381469727,3.5999999046325684,3.7300000190734863,18210,0.0,0.0,3.7894999742507935,3.9361249625682833,4.110708312193553,-1.5701268130783061,-3.7251100946200224,-4.247038134703075,45.75195870472492,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-01-20,3.7300000190734863,3.7950000762939453,3.565000057220459,3.690000057220459,5627,0.0,0.0,3.8034999847412108,3.9248749673366548,4.10579164425532,-2.9840917043798614,-3.0924547560251767,-4.406377444208541,44.15029122374872,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-01-23,3.7699999809265137,3.994999885559082,3.559999942779541,3.6449999809265137,75551,0.0,0.0,3.799999976158142,3.9131249725818633,4.100499975681305,-4.078947268529609,-2.8909119237528955,-4.569564789920741,42.35392577196962,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-01-24,3.7799999713897705,3.7799999713897705,3.5299999713897705,3.575000047683716,30014,0.0,0.0,3.7639999866485594,3.900124979019165,4.094624974330267,-5.02125238138292,-3.490272570825144,-4.750129658526657,39.65129011191867,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-01-25,3.634999990463257,3.640000104904175,3.505000114440918,3.619999885559082,17380,0.0,0.0,3.7429999828338625,3.890624976158142,4.0873333076636,-3.28613673093463,-3.7943773617074315,-4.812632508746877,42.20449631685242,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-01-26,3.619999885559082,3.640000104904175,3.515000104904175,3.625,41244,0.0,0.0,3.7204999923706055,3.877624976634979,4.080124976237615,-2.5668590933057724,-4.052093361558843,-4.963083258037014,42.49561664374502,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-01-27,3.625,3.634999990463257,3.5199999809265137,3.625,36148,0.0,0.0,3.6980000019073485,3.8646249771118164,4.070791643857956,-1.974040072192986,-4.3115431947809135,-5.064534979509592,42.49561664374502,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-01-30,3.6500000953674316,3.994999885559082,3.569999933242798,3.569999933242798,51995,0.0,0.0,3.664999985694885,3.849624973535538,4.061499977111817,-2.592088753694095,-4.795921397795046,-5.216668835904951,39.929785382292515,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-01-31,3.569999933242798,3.615000009536743,3.490000009536743,3.575000047683716,4631,0.0,0.0,3.64449999332428,3.8364999771118162,4.054833310842514,-1.9069816372031503,-5.004561056509566,-5.384520570719399,40.28279362854015,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-02-01,3.575000047683716,3.619999885559082,3.4600000381469727,3.575000047683716,9458,0.0,0.0,3.6230000019073487,3.8146249830722807,4.046374976634979,-1.3248676289915278,-5.023429092382186,-5.727348426700311,40.28279362854015,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-02-02,3.575000047683716,3.5999999046325684,3.4649999141693115,3.5299999713897705,15265,0.0,0.0,3.6029999971389772,3.796624982357025,4.038291643063228,-2.026090086238513,-5.099923909204257,-5.984378595372756,37.95473303131065,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-02-03,3.549999952316284,3.5999999046325684,3.5250000953674316,3.5299999713897705,12609,0.0,0.0,3.5869999885559083,3.7699999868869782,4.02804164091746,-1.589072131251538,-4.854111378450679,-6.406131739286301,37.95473303131065,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-02-06,3.5299999713897705,3.7200000286102295,3.5299999713897705,3.6449999809265137,9331,0.0,0.0,3.5869999885559083,3.7492499887943267,4.02020830710729,1.6169498900376529,-4.327532192394413,-6.739907428029005,47.02820285594433,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-02-07,3.684999942779541,3.884999990463257,3.6549999713897705,3.7950000762939453,14342,0.0,0.0,3.608999991416931,3.7358749926090242,4.013916639486949,5.153784575211059,-3.396125444322949,-6.9269412359660585,56.05532537785803,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-02-08,3.515000104904175,3.869999885559082,3.515000104904175,3.7950000762939453,7729,0.0,0.0,3.6265000104904175,3.724249988794327,4.0076249718666075,4.64635503422324,-2.624688960140253,-7.070895731550821,56.05532537785803,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-02-09,3.75,3.9749999046325684,3.6600000858306885,3.950000047683716,2828,0.0,0.0,3.659000015258789,3.7204999923706055,4.002208306392034,7.952993473938131,-1.6530030167431913,-7.038821881697277,63.50799408410665,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-02-10,3.6600000858306885,3.984999895095825,3.5399999618530273,3.9700000286102295,16461,0.0,0.0,3.693500018119812,3.717249995470047,3.996833308537801,7.486124519668219,-0.6389125665257226,-6.995120673922642,64.34816963809035,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-02-13,3.9700000286102295,3.984999895095825,3.7149999141693115,3.9000000953674316,6090,0.0,0.0,3.7265000343322754,3.714999997615814,3.988874975840251,4.6558448795571925,0.3095568431720507,-6.865970477471417,59.20987312120219,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-02-14,3.7300000190734863,3.8949999809265137,3.7249999046325684,3.8949999809265137,1315,0.0,0.0,3.758500027656555,3.713749998807907,3.9806666413942975,3.6317667225099672,1.204982264907775,-6.70532517872178,58.848392871662575,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-02-15,4.175000190734863,4.175000190734863,3.744999885559082,3.7950000762939453,9744,0.0,0.0,3.780500030517578,3.7123750030994414,3.9732083082199097,0.3835483576065978,1.8350793592042738,-6.56480317381919,52.009616267992044,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-02-16,4.09499979019165,4.09499979019165,3.799999952316284,3.8399999141693115,4840,0.0,0.0,3.8115000247955324,3.7139999985694887,3.9663749754428865,0.7477342040764645,2.625202645761915,-6.362862271871246,54.568200929101536,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-02-17,3.7950000762939453,4.09499979019165,3.7950000762939453,4.079999923706055,5422,0.0,0.0,3.8665000200271606,3.7196249961853027,3.9595416406790416,5.521787212544598,3.948651382665914,-6.0592024599239815,65.21882042296589,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-02-20,4.014999866485596,4.09499979019165,3.7200000286102295,3.994999885559082,39361,0.0,0.0,3.9015000104904174,3.7248749911785124,3.9537083049615225,2.396510952640283,4.7417703877364925,-5.787814783803002,59.86594290132168,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-02-21,4.09499979019165,4.09499979019165,3.7699999809265137,3.9800000190734863,10864,0.0,0.0,3.9200000047683714,3.7303749918937683,3.949083306392034,1.5306126079624904,5.083269464508653,-5.53820462952153,58.946498785962454,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-02-22,3.7699999809265137,3.994999885559082,3.765000104904175,3.865000009536743,8665,0.0,0.0,3.9269999980926515,3.734999990463257,3.9462916413942972,-1.5788130528653386,5.140562466389206,-5.3541823598315474,52.312896313641765,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-02-23,3.505000114440918,3.8949999809265137,3.505000114440918,3.875,44786,0.0,0.0,3.91949999332428,3.7418749928474426,3.941333309809367,-1.1353487281559507,4.746951750562635,-5.060681279238763,52.81020484834039,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-02-24,3.799999952316284,4.085000038146973,3.680000066757202,3.984999895095825,50375,0.0,0.0,3.9209999799728394,3.7527499914169313,3.9382499754428864,1.6322345179769442,4.48337856080793,-4.7102135512638235,57.99895151120327,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-02-27,3.984999895095825,3.984999895095825,3.700000047683716,3.8399999141693115,12369,0.0,0.0,3.9149999618530273,3.7608749866485596,3.933958307902018,-1.915710048901691,4.098114820397517,-4.399724341404218,50.16820298474599,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-02-28,3.8399999141693115,4.079999923706055,3.555000066757202,3.7950000762939453,19215,0.0,0.0,3.9049999713897705,3.7633749902248383,3.928791642189026,-2.816898742682366,3.763243937497468,-4.210369676718755,48.002138374666664,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-03-01,3.799999952316284,3.9549999237060547,3.700000047683716,3.75,7658,0.0,0.0,3.900499963760376,3.7693749904632567,3.9238333106040955,-3.8584787888392285,3.4786927177283538,-3.936413907375159,45.869328097830866,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-03-02,3.815000057220459,3.815000057220459,3.6649999618530273,3.7850000858306885,7760,0.0,0.0,3.8949999809265137,3.774749994277954,3.9191666464010875,-2.8241308250188806,3.1856410843325627,-3.6848816381857366,47.81158334675201,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-03-03,3.700000047683716,3.7850000858306885,3.5399999618530273,3.700000047683716,13442,0.0,0.0,3.85699999332428,3.77849999666214,3.9149999817212424,-4.070519728086608,2.0775439124384096,-3.486589672960606,43.70976820462937,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-03-06,3.7200000286102295,3.9000000953674316,3.609999895095825,3.890000104904175,57338,0.0,0.0,3.846500015258789,3.783749997615814,3.9116666495800017,1.13090054524435,1.6584081316819155,-3.27013172193295,53.344968355059464,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-03-07,3.8949999809265137,3.9000000953674316,3.690000057220459,3.9000000953674316,1295,0.0,0.0,3.8385000228881836,3.7828750014305115,3.9091666519641874,1.602190233490577,1.4704430211581738,-3.230654044135465,53.793262990606365,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-03-08,3.9000000953674316,3.9149999618530273,3.799999952316284,3.819999933242798,36832,0.0,0.0,3.834000015258789,3.7826250016689302,3.90645831823349,-0.36515602400294045,1.3581841596032278,-3.169963851567665,49.68055865385407,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-03-09,3.755000114440918,3.940000057220459,3.619999885559082,3.7850000858306885,17450,0.0,0.0,3.825000023841858,3.781000006198883,3.903916651010513,-1.045750006845576,1.1637137680729401,-3.1485468517831663,47.95322057195977,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-03-10,3.819999933242798,3.819999933242798,3.6600000858306885,3.734999895095825,8575,0.0,0.0,3.800000023841858,3.7781250059604643,3.902583316961924,-1.7105296931108114,0.5789913739456268,-3.1891263015583213,45.51839416780676,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-03-13,3.734999895095825,3.734999895095825,3.5450000762939453,3.640000104904175,24808,0.0,0.0,3.7800000429153444,3.771625006198883,3.9021249850591024,-3.703702021738443,0.22205380181477724,-3.344331085239262,41.23442948958577,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-03-14,3.5999999046325684,3.7200000286102295,3.5999999046325684,3.7200000286102295,7361,0.0,0.0,3.7725000381469727,3.7701250076293946,3.902291651566823,-1.391650338127785,0.06299606810840006,-3.386898154687177,45.85571873924476,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-03-15,3.5850000381469727,3.734999895095825,3.5799999237060547,3.5999999046325684,17948,0.0,0.0,3.7575000286102296,3.765375006198883,3.8979999860127768,-4.191620034023396,-0.20914192014577127,-3.4023853332425116,40.68710803367059,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-03-16,3.680000066757202,3.680000066757202,3.549999952316284,3.5799999237060547,2507,0.0,0.0,3.737000012397766,3.7616250038146974,3.8951666514078775,-4.201233293306188,-0.6546370622260059,-3.428393687466812,39.88029801407044,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-03-17,3.5,3.615000009536743,3.5,3.5950000286102295,3961,0.0,0.0,3.7265000104904176,3.7592500030994414,3.892916651566823,-3.52877986072734,-0.8711842144582547,-3.433586188226857,40.82801786312857,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-03-20,3.5950000286102295,3.5950000286102295,3.4649999141693115,3.5,5068,0.0,0.0,3.6875,3.7556250035762786,3.888166650136312,-5.084745762711865,-1.8139458415418697,-3.4088468547351654,36.864460375144624,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-03-21,3.575000047683716,3.575000047683716,3.440000057220459,3.549999952316284,2351,0.0,0.0,3.6524999856948854,3.755000001192093,3.8842916508515675,-2.8062979816576425,-2.729694153519762,-3.328577287216046,40.157285653007946,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-03-22,3.549999952316284,3.565000057220459,3.444999933242798,3.5,11118,0.0,0.0,3.6204999923706054,3.752000004053116,3.88008331656456,-3.3282693723113432,-3.5047977489460806,-3.3010454173661774,38.021727888983655,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-03-23,3.569999933242798,3.569999933242798,3.569999933242798,3.569999933242798,101,0.0,0.0,3.5989999771118164,3.7506250023841856,3.8781666497389478,-0.8057806072088664,-4.04266022798826,-3.2887098176492082,42.62221159392516,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-03-24,3.444999933242798,3.5450000762939453,3.444999933242798,3.5450000762939453,2738,0.0,0.0,3.5799999952316286,3.7486250042915343,3.8764999846617383,-0.9776513682765735,-4.498316285754349,-3.2987225816115218,41.439170933144396,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-03-27,3.569999933242798,4.494999885559082,3.569999933242798,3.690000057220459,10458,0.0,0.0,3.584999990463257,3.751625007390976,3.8747499843438464,2.9288721628039327,-4.441409165347164,-3.177623780898485,50.0918444221364,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-03-28,3.684999942779541,3.684999942779541,3.5450000762939453,3.5450000762939453,6063,0.0,0.0,3.5674999952316284,3.750875008106232,3.8723749856154126,-0.6306914917381028,-4.8888595988483,-3.1376087791216714,43.21536745407234,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-03-29,3.6600000858306885,4.045000076293945,3.5999999046325684,3.5999999046325684,13084,0.0,0.0,3.5674999952316284,3.751500004529953,3.8704583187898,0.9109995639629933,-4.90470502668649,-3.0734942599005324,46.230543594597364,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-03-30,3.7100000381469727,3.7100000381469727,3.5999999046325684,3.640000104904175,9312,0.0,0.0,3.5735000133514405,3.754250007867813,3.869208319981893,1.8609232210514686,-4.814543361192599,-2.971106815841283,48.37742021862557,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-03-31,3.5799999237060547,3.634999990463257,3.5450000762939453,3.630000114440918,4751,0.0,0.0,3.5770000219345093,3.7567500114440917,3.8683749874432882,1.4816911428964776,-4.784720542011437,-2.885577958743147,47.862911594340964,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-04-03,3.6500000953674316,3.9800000190734863,3.549999952316284,3.630000114440918,30437,0.0,0.0,3.590000033378601,3.756375014781952,3.8679166555404665,1.1142083757774297,-4.429136621041243,-2.883765362388058,47.862911594340964,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-04-04,3.7300000190734863,3.8399999141693115,3.7300000190734863,3.8399999141693115,9580,0.0,0.0,3.619000029563904,3.757500010728836,3.8692083219687143,6.106656059686146,-3.6859608987217887,-2.887110280560947,58.58925425166642,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-04-05,3.9200000762939453,3.990000009536743,3.680000066757202,3.930000066757202,22794,0.0,0.0,3.662000036239624,3.7608750104904174,3.870791655778885,7.318406003970923,-2.629041751586953,-2.839642508900421,62.180383691510045,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-04-06,3.799999952316284,3.950000047683716,3.7100000381469727,3.819999933242798,25624,0.0,0.0,3.687000036239624,3.7576250076293944,3.865124988555908,3.6072659532387905,-1.8795108944180197,-2.7812808445989696,55.81001199135761,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-04-11,3.819999933242798,4.480000019073486,3.5899999141693115,3.8399999141693115,10328,0.0,0.0,3.7165000200271607,3.7543750047683715,3.8631249884764354,3.3230161032327463,-1.0088226320787441,-2.815078052935414,56.67903357867544,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-04-12,3.8399999141693115,3.8399999141693115,3.700000047683716,3.809999942779541,11964,0.0,0.0,3.728500008583069,3.7521250009536744,3.8590416530768077,2.1858638596984834,-0.6296429986900973,-2.770549315991156,54.93392188288832,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-04-13,3.75,3.7899999618530273,3.509999990463257,3.7899999618530273,12451,0.0,0.0,3.752999997138977,3.749500000476837,3.85783331990242,0.9858770248402976,0.09334569040391955,-2.808138932978138,53.74585954233881,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-04-14,3.7899999618530273,3.7899999618530273,3.5799999237060547,3.5999999046325684,11097,0.0,0.0,3.752999997138977,3.7446249961853026,3.8536666532357535,-4.076741077086205,0.22365392962462766,-2.8295560270863964,44.00844826876452,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-04-17,3.680000066757202,3.819999933242798,3.5,3.5199999809265137,23573,0.0,0.0,3.7409999847412108,3.736624997854233,3.8491249859333037,-5.907511486664309,0.11708391635473568,-2.9227418826409615,40.667523108334485,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-04-18,3.509999990463257,3.950000047683716,3.430000066757202,3.950000047683716,21369,0.0,0.0,3.772999978065491,3.733375000953674,3.848833320538203,4.691229012648371,1.061371469560241,-2.999826440090779,58.78070894778843,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-04-19,3.950000047683716,3.950000047683716,3.5899999141693115,3.680000066757202,2932,0.0,0.0,3.7779999732971192,3.725500005483627,3.846208322048187,-2.5939626054150295,1.4092059518512008,-3.1383717796200963,48.72266952713207,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-04-20,3.680000066757202,3.8399999141693115,3.6600000858306885,3.680000066757202,18285,0.0,0.0,3.761999988555908,3.7180000066757204,3.843541655937831,-2.1796895812905803,1.1834314631841083,-3.2663012528604436,48.72266952713206,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-04-21,3.759999990463257,3.7799999713897705,3.5399999618530273,3.609999895095825,25922,0.0,0.0,3.7299999713897707,3.711625003814697,3.8382499893506368,-3.217160247034381,0.49506530310007796,-3.299029137947377,46.33856218005558,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-04-24,3.609999895095825,3.7799999713897705,3.5399999618530273,3.680000066757202,20436,0.0,0.0,3.715999984741211,3.7067500054836273,3.8346249918142954,-0.9687814351946452,0.24954418948943025,-3.3347455514852298,49.02476411863044,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-04-25,3.680000066757202,3.759999990463257,3.5299999713897705,3.5799999237060547,31860,0.0,0.0,3.689999985694885,3.6966250061988832,3.829874990383784,-2.981031501768845,-0.17921808387079127,-3.4792254190925473,45.51920555793472,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-04-26,3.640000104904175,3.6600000858306885,3.630000114440918,3.6600000858306885,1296,0.0,0.0,3.675,3.6921250104904173,3.827374990781148,-0.4081609297771795,-0.463825315821113,-3.5337530452726016,48.68073390331986,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-04-27,3.6600000858306885,3.890000104904175,3.5399999618530273,3.5999999046325684,32302,0.0,0.0,3.655999994277954,3.687250006198883,3.822583321730296,-1.5317311196124779,-0.8475154076450525,-3.540362737473421,46.501197326831495,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-04-28,3.619999885559082,3.8299999237060547,3.430000066757202,3.630000114440918,29140,0.0,0.0,3.659000015258789,3.684250009059906,3.821166656414668,-0.7925635609985127,-0.685349629884644,-3.5831111193466776,47.76059158303298,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-05-02,3.630000114440918,3.630000114440918,3.490000009536743,3.5,20083,0.0,0.0,3.657000017166138,3.677125006914139,3.816999989748001,-4.293136899895326,-0.5473023003068886,-3.664526675649708,43.0331623757234,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-05-03,3.5,3.549999952316284,3.380000114440918,3.450000047683716,46355,0.0,0.0,3.6070000171661376,3.6708750069141387,3.812624990940094,-4.3526467628289565,-1.7400480710373347,-3.717910478024838,41.338359796108804,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-05-04,3.490000009536743,3.5399999618530273,3.4800000190734863,3.509999990463257,14700,0.0,0.0,3.5900000095367433,3.6613750040531157,3.808708324035009,-2.228412781642574,-1.9494041019387744,-3.8683277228697257,44.17939317946322,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-05-05,3.569999933242798,3.569999933242798,3.4100000858306885,3.4100000858306885,6726,0.0,0.0,3.5630000114440916,3.649125003814697,3.8046249906222025,-4.294132055065359,-2.3601546200958534,-4.087130458081628,40.64613911473774,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-05-08,3.4100000858306885,3.799999952316284,3.4100000858306885,3.559999942779541,25537,0.0,0.0,3.558000016212463,3.642625004053116,3.800083323319753,0.05620929055550601,-2.3231869255410915,-4.143549124314506,47.43681131415703,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-05-09,3.559999942779541,3.559999942779541,3.4700000286102295,3.5,9212,0.0,0.0,3.540000009536743,3.6355000019073485,3.795916656653086,-1.129943769180315,-2.626873671310737,-4.226032056435596,45.208731283552986,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-05-10,3.5,3.7200000286102295,3.5,3.5399999618530273,21225,0.0,0.0,3.5360000133514404,3.6306250035762786,3.791124991575877,0.11312071511548837,-2.606300296274873,-4.233571521810534,46.99610953883129,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-05-11,3.619999885559082,3.619999885559082,3.450000047683716,3.5199999809265137,10574,0.0,0.0,3.5220000028610228,3.6276250004768373,3.787124991416931,-0.05678653983203929,-2.91168457604991,-4.211637886301128,46.18485087719387,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-05-12,3.5,3.809999942779541,3.450000047683716,3.5199999809265137,26926,0.0,0.0,3.5140000104904177,3.6226249992847444,3.7822916587193807,0.1707447472448542,-2.9985159605472202,-4.221426421903612,46.18485087719387,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-05-15,3.5399999618530273,3.8399999141693115,3.4600000381469727,3.5199999809265137,10802,0.0,0.0,3.502999997138977,3.620625001192093,3.7774166584014894,0.48529785330919256,-3.2487486004319095,-4.150764170022662,46.184850877193874,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-05-16,3.5999999046325684,3.680000066757202,3.4800000190734863,3.549999952316284,27358,0.0,0.0,3.5079999923706056,3.6198750019073485,3.7725416560967764,1.1972622587520663,-3.090576593882243,-4.046785114823172,47.870722325941,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-05-17,3.5799999237060547,3.640000104904175,3.4800000190734863,3.5399999618530273,22378,0.0,0.0,3.5169999837875365,3.6185000002384187,3.7675416568915048,0.653965828021461,-2.8050301628905463,-3.9559391833256146,47.338373054412585,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-05-19,3.5799999237060547,3.5799999237060547,3.4000000953674316,3.450000047683716,13091,0.0,0.0,3.5109999895095827,3.6172500014305116,3.7619999925295513,-1.7373951013422637,-2.9373145864651393,-3.847687171357768,42.732497954422136,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-05-22,3.3499999046325684,3.4600000381469727,3.1600000858306885,3.309999942779541,31162,0.0,0.0,3.5009999752044676,3.6112500011920927,3.75545832713445,-5.455585083623763,-3.052960220179467,-3.8399660808483413,36.74354581644949,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-05-23,3.309999942779541,3.3299999237060547,3.2699999809265137,3.3299999237060547,3828,0.0,0.0,3.477999973297119,3.6069999992847444,3.749874993165334,-4.255320607457087,-3.5763799837317896,-3.8101268479882453,38.078661209769955,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-05-24,3.2899999618530273,3.2899999618530273,3.2100000381469727,3.240000009536743,25267,0.0,0.0,3.4519999742507936,3.598750001192093,3.742333326737086,-6.141366346912038,-4.077805540609604,-3.8367326747503405,34.54521077907482,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-05-25,3.240000009536743,3.299999952316284,3.2200000286102295,3.299999952316284,10266,0.0,0.0,3.427999973297119,3.5926249980926515,3.7352916598320007,-3.7339563004057426,-4.582304718219487,-3.8194249534390012,38.63350440483099,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-05-26,3.299999952316284,3.299999952316284,3.25,3.2899999618530273,2958,0.0,0.0,3.4049999713897705,3.5826249957084655,3.7279583255449933,-3.377386505228229,-4.95795749014947,-3.8984698096184163,38.20519607867489,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-05-29,3.2899999618530273,3.299999952316284,3.240000009536743,3.299999952316284,2030,0.0,0.0,3.3829999685287477,3.576499992609024,3.721291659275691,-2.453444191090546,-5.410318033836195,-3.890898105386585,38.93427511825968,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-05-30,3.299999952316284,3.299999952316284,3.240000009536743,3.2899999618530273,4012,0.0,0.0,3.359999966621399,3.5687499940395355,3.71162499388059,-2.0833334959452183,-5.849387818333789,-3.8493921146833108,38.445784680317125,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-05-31,3.2200000286102295,3.2899999618530273,2.3499999046325684,2.990000009536743,101513,0.0,0.0,3.303999972343445,3.55249999165535,3.701124993960063,-9.503630915105289,-6.9950744516712,-4.015670979695549,27.356731526969924,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-06-01,3.0,3.180000066757202,2.9000000953674316,3.0,50289,0.0,0.0,3.249999976158142,3.536749988794327,3.687833329041799,-7.692307015142495,-8.107726402621331,-4.096805000857453,28.101173109777264,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-06-02,2.990000009536743,3.0,2.9000000953674316,3.0,4218,0.0,0.0,3.2049999713897703,3.5209999859333037,3.6755416631698608,-6.396255014656899,-8.974723538937246,-4.20459598608596,28.101173109777264,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-06-05,2.9000000953674316,2.990000009536743,2.9000000953674316,2.9000000953674316,356,0.0,0.0,3.1639999866485597,3.4974999904632567,3.6636249979337054,-8.343865119947987,-9.535382551081112,-4.534443551513698,25.116088662602877,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-06-07,3.0,3.0899999141693115,2.859999895095825,3.0899999141693115,25783,0.0,0.0,3.1399999856948853,3.4764999866485597,3.653874995311101,-1.5923589730370225,-9.679275197641225,-4.854435603028592,38.486402016494964,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-06-08,3.0899999141693115,3.4000000953674316,3.0899999141693115,3.200000047683716,20615,0.0,0.0,3.1359999895095827,3.4609999895095824,3.646374996503194,2.040818188399983,-9.39034963840181,-5.083816315419636,44.648226387588316,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-06-09,3.2100000381469727,3.2699999809265137,3.0399999618530273,3.2200000286102295,10035,0.0,0.0,3.127999997138977,3.4454999923706056,3.639041664203008,2.9411774793925867,-9.214917891007717,-5.318479140710531,45.712994711775345,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-06-12,3.2200000286102295,3.2200000286102295,3.049999952316284,3.1500000953674316,6085,0.0,0.0,3.1140000104904173,3.428999996185303,3.6320416649182636,1.1560720859260614,-9.186351299076028,-5.5902901856587075,42.62258476912082,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-06-13,3.1600000858306885,3.2200000286102295,3.0999999046325684,3.0999999046325684,14153,0.0,0.0,3.094000005722046,3.4117499947547913,3.6249999980131786,0.19392045570220856,-9.313401905803559,-5.882758713800474,40.51561837204693,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-06-14,3.549999952316284,3.549999952316284,2.8299999237060547,2.9000000953674316,47720,0.0,0.0,3.0550000190734865,3.3942499995231628,3.617083332935969,-5.073647225477363,-9.99484364726627,-6.160580581148336,33.4027786094133,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-06-15,3.059999942779541,3.059999942779541,2.990000009536743,2.990000009536743,1581,0.0,0.0,3.0550000190734865,3.3810000002384184,3.6105416655540465,-2.1276598733526817,-9.642117158886226,-6.35754096138936,38.62449000161628,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-06-16,2.990000009536743,2.990000009536743,2.9100000858306885,2.990000009536743,5576,0.0,0.0,3.0540000200271606,3.3569999992847444,3.6033333321412404,-2.0956126414775955,-9.025915380462974,-6.836262708732396,38.62449000161628,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-06-19,2.9100000858306885,2.930000066757202,2.7100000381469727,2.9200000762939453,47613,0.0,0.0,3.046000027656555,3.337999999523163,3.5961249987284343,-4.136570919848219,-8.747752304023976,-7.177865043527206,36.07316436687772,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-06-20,2.8399999141693115,2.8499999046325684,2.8399999141693115,2.8399999141693115,585,0.0,0.0,3.040000009536743,3.3169999957084655,3.5884583314259846,-6.578950484868877,-8.350919099490657,-7.5647620968653335,33.36097624142229,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-06-21,2.9200000762939453,2.930000066757202,2.799999952316284,2.8399999141693115,91066,0.0,0.0,3.015000009536743,3.2977499961853027,3.581458330154419,-5.804314919200297,-8.57402735124351,-7.921586901637462,33.36097624142229,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-06-22,2.880000114440918,2.930000066757202,2.859999895095825,2.9200000762939453,10213,0.0,0.0,2.987000012397766,3.2787499964237212,3.5757916649182637,-2.24305108221401,-8.898207681103466,-8.307018314539652,38.70569730885304,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-06-26,2.859999895095825,2.880000114440918,2.799999952316284,2.799999952316284,9060,0.0,0.0,2.9450000047683718,3.2592499971389772,3.5695416649182636,-4.923601093966451,-9.64178852946105,-8.692759376612894,34.26616309334979,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-06-27,2.880000114440918,3.0,2.759999990463257,2.880000114440918,35673,0.0,0.0,2.91800000667572,3.239749997854233,3.56424999833107,-1.3022581270687816,-9.93132159554335,-9.10429965992233,39.26740865816578,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-06-28,2.7799999713897705,2.8399999141693115,2.7799999713897705,2.8399999141693115,5441,0.0,0.0,2.8920000076293944,3.2207499980926513,3.557124998172124,-1.7980668507227255,-10.207249574103695,-9.456372780049154,37.72201180026966,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-06-29,2.8399999141693115,2.890000104904175,2.759999990463257,2.890000104904175,16464,0.0,0.0,2.891000008583069,3.2022499978542327,3.5519583324591317,-0.034586775369267554,-9.719727987500242,-9.845507798026027,40.85541957457378,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-06-30,2.8399999141693115,2.859999895095825,2.7799999713897705,2.8499999046325684,26944,0.0,0.0,2.8769999980926513,3.185999995470047,3.5459583322207133,-0.9384808299611755,-9.698681664053407,-10.151228610891108,39.15804185902649,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-07-03,2.8499999046325684,2.9000000953674316,2.7799999713897705,2.9000000953674316,17674,0.0,0.0,2.8680000066757203,3.17224999666214,3.5405416667461393,1.1157632014374514,-9.590984011554989,-10.402127830978763,42.38053654400571,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-07-04,2.9000000953674316,2.9000000953674316,2.8499999046325684,2.8499999046325684,9246,0.0,0.0,2.8609999895095823,3.1557499945163725,3.5336249987284343,-0.3844839188167757,-9.34009365504131,-10.693692860675345,40.093626656729455,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-07-05,2.8299999237060547,2.9100000858306885,2.7899999618530273,2.890000104904175,15343,0.0,0.0,2.866000008583069,3.14274999499321,3.5249166667461393,0.8374074057651961,-8.805981603724058,-10.841864017900562,42.754938788097746,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-07-06,2.8399999141693115,3.059999942779541,2.799999952316284,3.0,49009,0.0,0.0,2.8820000171661375,3.1287499964237213,3.5180000007152556,4.094378283518941,-7.886535502664907,-11.064525418203374,49.41067983718357,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-07-07,3.0,3.069999933242798,2.8499999046325684,2.9100000858306885,57280,0.0,0.0,2.881000018119812,3.1139999985694886,3.5101666688919066,1.006597276240293,-7.4823372047756,-11.286263807167892,44.81915857985324,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-07-10,2.9100000858306885,2.9100000858306885,2.799999952316284,2.9100000858306885,26046,0.0,0.0,2.8920000314712526,3.09825000166893,3.5023333370685577,0.6224085118795333,-6.656982815672623,-11.53754644433257,44.81915857985324,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-07-11,2.880000114440918,2.930000066757202,2.799999952316284,2.859999895095825,33766,0.0,0.0,2.890000009536743,3.0817499995231628,3.493666668732961,-1.0380662402048502,-6.222113734601737,-11.790382662899754,42.28727131316377,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-07-12,2.8299999237060547,2.8499999046325684,2.7899999618530273,2.7899999618530273,12850,0.0,0.0,2.8850000143051147,3.063499999046326,3.485416668653488,-3.292896082531534,-5.8266683465571605,-12.105200316556703,38.96830510455243,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-07-13,2.8399999141693115,2.890000104904175,2.75,2.8399999141693115,22743,0.0,0.0,2.8799999952316284,3.0464999973773956,3.477500001589457,-1.3888917058522365,-5.465288110589204,-12.393961294466276,42.44323609523785,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-07-14,2.8399999141693115,2.8399999141693115,2.7200000286102295,2.799999952316284,21339,0.0,0.0,2.875,3.027749997377396,3.4697500010331472,-2.608697310737942,-5.045000330598834,-12.7386700345599,40.45862008693807,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-07-17,2.799999952316284,2.799999952316284,2.680000066757202,2.7100000381469727,10286,0.0,0.0,2.855999994277954,3.0069999992847443,3.4615833342075346,-5.112043292139171,-5.021616396498428,-13.132237217303878,36.34112091154792,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-07-18,2.740000009536743,3.049999952316284,2.7100000381469727,3.049999952316284,59927,0.0,0.0,2.875999999046326,2.9969999969005583,3.456625000635783,6.050067918207797,-4.037370636615561,-13.296929914314829,54.98089689399366,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-07-19,3.049999952316284,3.049999952316284,2.940000057220459,2.990000009536743,1789,0.0,0.0,2.8859999895095827,2.9889999985694886,3.4517500003178916,3.6036043106442683,-3.445968856112442,-13.406243259383954,52.082674605696084,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-07-20,2.9000000953674316,2.950000047683716,2.819999933242798,2.859999895095825,28568,0.0,0.0,2.871999979019165,2.9772499978542326,3.445416667064031,-0.4178302232243772,-3.5351421248105965,-13.588100205271855,46.37825039278633,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-07-21,2.8299999237060547,2.8499999046325684,2.819999933242798,2.8499999046325684,16089,0.0,0.0,2.865999960899353,2.9674999952316283,3.438958332935969,-0.558271335836437,-3.4203886940310775,-13.709335562139213,45.96123626112033,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-07-24,2.8499999046325684,2.8499999046325684,2.799999952316284,2.8499999046325684,3545,0.0,0.0,2.859999942779541,2.9562499940395357,3.432499998807907,-0.3496516904561113,-3.255815694006143,-13.874727019192163,45.96123626112033,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-07-25,2.809999942779541,2.8499999046325684,2.759999990463257,2.8499999046325684,12231,0.0,0.0,2.8589999437332154,2.945249992609024,3.4264999985694886,-0.31479675683011804,-2.9284457717426084,-14.044944000040251,45.96123626112033,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-07-26,2.859999895095825,2.869999885559082,2.700000047683716,2.799999952316284,21804,0.0,0.0,2.859999942779541,2.932749992609024,3.4200416644414267,-2.0979018064225774,-2.4806086442016704,-14.248120919076252,43.51765944955551,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-07-27,2.799999952316284,2.799999952316284,2.799999952316284,2.799999952316284,0,0.0,0.0,2.8559999465942383,2.9204999923706056,3.4135833303133647,-1.9607841500394192,-2.2085275105243842,-14.444742964499252,43.51765944955551,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-07-28,2.740000009536743,2.8499999046325684,2.740000009536743,2.8499999046325684,11120,0.0,0.0,2.8609999418258667,2.916999989748001,3.407916663090388,-0.38448225854482915,-1.9197822461073144,-14.40518421883037,46.79809026000601,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-07-31,2.799999952316284,2.880000114440918,2.5,2.880000114440918,39306,0.0,0.0,2.877999949455261,2.913999992609024,3.402499997615814,0.06949843713636969,-1.2354167208329503,-14.357090531935047,48.722443964915215,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-08-01,2.8399999141693115,2.880000114440918,2.759999990463257,2.809999942779541,22005,0.0,0.0,2.853999948501587,2.9092499911785126,3.3955416639645892,-1.5416960937629647,-1.899116364851968,-14.321475655765889,44.663012724980724,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-08-02,2.759999990463257,2.869999885559082,2.7200000286102295,2.7899999618530273,21862,0.0,0.0,2.8339999437332155,2.9064999878406526,3.387166663010915,-1.5525752559552697,-2.4944106110697093,-14.190818551071505,43.54664822483486,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-08-03,2.75,2.799999952316284,2.700000047683716,2.7799999713897705,23286,0.0,0.0,2.82599995136261,2.898749989271164,3.37870832880338,-1.6277417114129697,-2.5097037750001263,-14.205379477138838,42.96833750697239,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-08-04,2.799999952316284,2.859999895095825,2.759999990463257,2.859999895095825,12980,0.0,0.0,2.8269999504089354,2.8902499854564665,3.3696249941984813,1.1673132389732186,-2.188393231236081,-14.226360783985154,48.823654940955706,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-08-07,2.859999895095825,2.890000104904175,2.7799999713897705,2.890000104904175,18606,0.0,0.0,2.830999970436096,2.881999987363815,3.360624994834264,2.084074005094039,-1.769605036479164,-14.242142702805587,50.861069995701584,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-08-08,2.7100000381469727,3.0199999809265137,2.7100000381469727,2.859999895095825,16915,0.0,0.0,2.831999969482422,2.874749982357025,3.3519583264986674,0.9886979489805724,-1.4870862905285422,-14.236702776675529,48.77009642937942,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-08-09,2.9100000858306885,2.9100000858306885,2.7100000381469727,2.799999952316284,12831,0.0,0.0,2.831999969482422,2.867249983549118,3.3428333262602488,-1.1299441211500512,-1.2294014916363485,-14.226953494064375,44.80292769926231,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-08-10,2.819999933242798,2.8299999237060547,2.700000047683716,2.7699999809265137,44784,0.0,0.0,2.828999972343445,2.863999980688095,3.3342916587988536,-2.0855423115489713,-1.222067338710003,-14.104695276722634,42.92287281818043,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-08-11,2.7699999809265137,2.819999933242798,2.7200000286102295,2.7699999809265137,44100,0.0,0.0,2.8209999799728394,2.8584999799728394,3.325374992688497,-1.8078695288334143,-1.3118768676834625,-14.03977036400934,42.92287281818043,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-08-14,2.7300000190734863,2.7699999809265137,2.690000057220459,2.759999990463257,2347,0.0,0.0,2.8089999675750734,2.8527499794960023,3.3143749932448068,-1.7443922277477566,-1.5336083510780787,-13.927965745869598,42.237680779447295,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-08-15,2.759999990463257,2.759999990463257,2.680000066757202,2.680000066757202,8158,0.0,0.0,2.7959999799728394,2.8467499792575834,3.303416661421458,-4.14878090295137,-1.7827346853262933,-13.824071528638813,37.131039983290464,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-08-16,2.640000104904175,2.7100000381469727,2.640000104904175,2.7100000381469727,1511,0.0,0.0,2.787999987602234,2.843499982357025,3.2928333282470703,-2.797702647134644,-1.9518197678617986,-13.645796828995485,40.0577792007017,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-08-17,2.549999952316284,2.990000009536743,2.5,2.759999990463257,58289,0.0,0.0,2.7859999895095826,2.841499984264374,3.283624994754791,-0.9332375859377706,-1.9531935619263914,-13.46454029301947,44.68012442794822,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-08-18,3.0,3.0,2.75,2.759999990463257,1516,0.0,0.0,2.7759999990463258,2.8374999821186067,3.2743333280086517,-0.5763691854670613,-2.1674002981442206,-13.34113855035381,44.68012442794822,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-08-21,2.8499999046325684,2.9100000858306885,2.680000066757202,2.7699999809265137,76983,0.0,0.0,2.7639999866485594,2.8367499828338625,3.2642083287239076,0.21707649446226912,-2.5645543888442064,-13.095314478814332,45.65222386027391,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-08-22,2.7699999809265137,2.9100000858306885,2.690000057220459,2.859999895095825,29397,0.0,0.0,2.7639999866485594,2.836249977350235,3.256041661898295,3.4732239113962096,-2.547377391931268,-12.892700036992727,53.56147093851208,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-08-23,2.859999895095825,2.9200000762939453,2.819999933242798,2.9100000858306885,19778,0.0,0.0,2.775,2.8379999816417696,3.2486666619777678,4.864867957862652,-2.21987251759334,-12.641083960457392,57.28100579520541,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-08-24,2.9100000858306885,2.9100000858306885,2.7200000286102295,2.7799999713897705,40914,0.0,0.0,2.7759999990463258,2.835249978303909,3.240583328406016,0.14409122279606976,-2.089762091913589,-12.508036641090884,46.787970330286846,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-08-25,2.9000000953674316,2.9100000858306885,2.819999933242798,2.9100000858306885,17686,0.0,0.0,2.790000009536743,2.8367499828338625,3.2332916617393495,4.301077988665331,-1.648011759232201,-12.264333700479323,55.555769275891976,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-08-28,2.9100000858306885,2.990000009536743,2.9100000858306885,2.990000009536743,4336,0.0,0.0,2.8130000114440916,2.838999980688095,3.227374994754791,6.292214623980261,-0.9158143508582101,-12.033774033011122,59.9311709667467,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-08-29,2.990000009536743,2.990000009536743,2.509999990463257,2.759999990463257,32394,0.0,0.0,2.821000003814697,2.8367499828338625,3.21795832713445,-2.162354245620456,-0.5552120953370504,-11.846279707420843,45.931047408870555,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-08-30,2.759999990463257,2.8299999237060547,2.680000066757202,2.7899999618530273,6317,0.0,0.0,2.8289999961853027,2.8342499792575837,3.20870832602183,-1.3785802186236853,-0.18523359303882495,-11.670064983080012,47.648887263485136,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-08-31,2.7899999618530273,2.7899999618530273,2.630000114440918,2.740000009536743,32696,0.0,0.0,2.8269999980926515,2.8277499794960024,3.199708326657613,-3.077466877064249,-0.026522196403113055,-11.624757921299507,45.07828135976355,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-09-01,2.740000009536743,2.7799999713897705,2.700000047683716,2.700000047683716,9851,0.0,0.0,2.821000003814697,2.8224999785423277,3.190666659673055,-4.2892575670811475,-0.053143480568073706,-11.538863830057794,43.07614242121075,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-09-04,2.680000066757202,2.759999990463257,2.5899999141693115,2.5899999141693115,9840,0.0,0.0,2.802999997138977,2.8144999742507935,3.181124993165334,-7.5990040380690225,-0.4085975205907662,-11.525011425273657,38.06872789011651,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-09-05,2.680000066757202,2.7100000381469727,2.5399999618530273,2.6500000953674316,25609,0.0,0.0,2.782000017166138,2.809249979257584,3.1728749930858613,-4.744785082106754,-0.9700084468327529,-11.460426730352355,42.0273489854653,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-09-06,2.619999885559082,2.619999885559082,2.4200000762939453,2.5299999713897705,51271,0.0,0.0,2.7440000057220457,2.802749979496002,3.1629583259423573,-7.798835054155331,-2.0961546411114726,-11.388336782434097,36.94151219333096,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-09-07,2.549999952316284,2.549999952316284,2.4000000953674316,2.5,85559,0.0,0.0,2.7160000085830687,2.7942499816417694,3.1537916600704192,-7.952872161283807,-2.8003927197925487,-11.400298979185639,35.77592407337775,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-09-08,2.5,2.9800000190734863,2.450000047683716,2.5199999809265137,81924,0.0,0.0,2.6769999980926515,2.787249982357025,3.144958327213923,-5.86477464617107,-3.9555111655661834,-11.374024951668817,37.19855903069503,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-09-11,2.509999990463257,2.5799999237060547,2.5,2.5,17294,0.0,0.0,2.627999997138977,2.781999981403351,3.1358333269755048,-4.870623945141812,-5.535585380798245,-11.2835507719227,36.331860747730694,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-09-12,2.4800000190734863,2.509999990463257,2.430000066757202,2.5,29886,0.0,0.0,2.6019999980926514,2.7682499825954436,3.127499993642171,-3.920061420731,-6.005598683212863,-11.486810928122756,36.33186074773068,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-09-13,2.4800000190734863,2.5,2.4600000381469727,2.5,16259,0.0,0.0,2.5730000019073485,2.755999982357025,3.1187499940395353,-2.837155143926701,-6.64005738828666,-11.631262921868938,36.331860747730694,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-09-14,2.5,2.5,2.380000114440918,2.4600000381469727,52696,0.0,0.0,2.5450000047683714,2.7459999859333037,3.1100833276907602,-3.339880804013392,-7.3197371520239445,-11.706546204592811,34.33363021592689,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-09-15,2.4000000953674316,2.440000057220459,2.359999895095825,2.440000057220459,30205,0.0,0.0,2.519000005722046,2.735749989748001,3.100666662057241,-3.1361630933757203,-7.922872515332462,-11.768974613579509,33.34608389437176,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-09-18,2.430000066757202,2.430000066757202,2.299999952316284,2.3299999237060547,51028,0.0,0.0,2.4930000066757203,2.7227499902248384,3.090541660785675,-6.538310570926044,-8.438159374674935,-11.90055695503347,28.49198355415197,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-09-19,2.3299999237060547,2.5899999141693115,2.2200000286102295,2.380000114440918,81754,0.0,0.0,2.4660000085830687,2.710999995470047,3.0796249945958456,-3.48742473004147,-9.037255156634515,-11.96980151066007,33.24849049004425,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-09-20,2.3499999046325684,2.359999895095825,2.3299999237060547,2.3299999237060547,17374,0.0,0.0,2.446000003814697,2.6992499947547914,3.0694999933242797,-4.742439898926114,-9.382235488828826,-12.062225097726948,31.025981073957098,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-09-21,2.369999885559082,2.380000114440918,2.369999885559082,2.380000114440918,2695,0.0,0.0,2.434000015258789,2.688749998807907,3.0593333284060162,-2.2185661659550027,-9.474662339825748,-12.11320538880906,35.65780690033837,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-09-22,2.309999942779541,2.549999952316284,2.309999942779541,2.4800000190734863,24438,0.0,0.0,2.4300000190734865,2.67950000166893,3.0496666610240935,2.057613152573714,-9.311438045905653,-12.137938355231904,43.788122225193824,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-09-25,2.5,2.9800000190734863,2.4600000381469727,2.9800000190734863,25933,0.0,0.0,2.478000020980835,2.681999999284744,3.0442499935626985,20.25827255215079,-7.606263175179466,-11.899482468389916,66.54858614918928,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-09-26,2.8499999046325684,2.8499999046325684,2.4600000381469727,2.5799999237060547,61567,0.0,0.0,2.4860000133514406,2.676249998807907,3.035499991973241,3.7811709513183143,-7.108827110367498,-11.834952861647086,49.33759837876574,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-09-27,2.609999895095825,2.609999895095825,2.5199999809265137,2.609999895095825,61,0.0,0.0,2.497000002861023,2.671749997138977,3.0252499918142957,4.525426195647932,-6.540656665671703,-11.684984567616464,50.374218772404106,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-09-28,2.569999933242798,2.9800000190734863,2.5299999713897705,2.7200000286102295,34208,0.0,0.0,2.5230000019073486,2.6702499985694885,3.0151666581630705,7.808165935551008,-5.514464815692349,-11.439389549488965,54.08405357210273,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-09-29,2.7200000286102295,2.890000104904175,2.7200000286102295,2.890000104904175,16434,0.0,0.0,2.56800000667572,2.6710000038146973,3.007416659593582,12.538944602468455,-3.8562335077451735,-11.186233696808332,59.16474764524082,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-10-02,2.890000104904175,3.2799999713897705,2.740000009536743,3.190000057220459,116218,0.0,0.0,2.6540000200271607,2.6785000026226045,3.0019999941190085,20.195931919692033,-0.9146904077451938,-10.776148971690489,66.25991211415854,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-10-03,3.190000057220459,3.2699999809265137,3.0,3.140000104904175,91943,0.0,0.0,2.7300000190734863,2.6855000078678133,2.996416662136714,15.018318057368923,1.6570475172332764,-10.376282384145773,64.25602090905787,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-10-04,3.2300000190734863,3.4200000762939453,3.200000047683716,3.4000000953674316,25789,0.0,0.0,2.837000036239624,2.700500011444092,2.9931666632493337,19.84490842213914,5.054620411667348,-9.777826787885164,69.43287884590572,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-10-05,3.4000000953674316,3.799999952316284,3.3299999237060547,3.700000047683716,83348,0.0,0.0,2.9690000295639036,2.7237500131130217,2.99399999777476,24.62108490538425,9.004130895646382,-9.026385599953135,74.09496295645957,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-10-06,3.700000047683716,3.890000104904175,3.3399999141693115,3.75,70409,0.0,0.0,3.0960000276565554,2.748250013589859,2.9959166646003723,21.124029925751472,12.653507226311378,-8.266807082350859,74.78522462619661,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-10-09,3.75,3.859999895095825,3.559999942779541,3.799999952316284,35859,0.0,0.0,3.178000020980835,2.774250012636185,2.994666663805644,19.572055608214875,14.553483157813638,-7.360306702361054,75.48859241403811,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-10-10,3.799999952316284,3.880000114440918,3.5999999046325684,3.880000114440918,35482,0.0,0.0,3.3080000400543215,2.8042500138282778,2.9963333308696747,17.291416791434003,17.963805785573996,-6.410612432951359,76.6127136812702,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-10-11,3.880000114440918,3.880000114440918,3.5,3.6700000762939453,82248,0.0,0.0,3.414000058174133,2.828250014781952,2.996249997615814,7.498535845272521,20.71068824646822,-5.607008192492075,67.8201262338008,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-10-12,3.619999885559082,3.880000114440918,3.490000009536743,3.609999895095825,58905,0.0,0.0,3.503000044822693,2.8495000123977663,2.996249997615814,3.054520379789156,22.933849081650866,-4.897788413344021,65.5068863091197,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-10-13,3.619999885559082,3.6600000858306885,3.4600000381469727,3.6600000858306885,33045,0.0,0.0,3.5800000429153442,2.872000014781952,2.9960833311080934,2.23463804347323,24.651811437652274,-4.141517528494428,66.53136714853404,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-10-16,3.890000104904175,3.890000104904175,3.200000047683716,3.7100000381469727,22730,0.0,0.0,3.632000041007996,2.8955000162124636,2.997166665395101,2.1475769894906,25.436022126462664,-3.392091949922813,67.56870064504048,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-10-17,3.7100000381469727,3.859999895095825,3.299999952316284,3.630000114440918,49488,0.0,0.0,3.6810000419616697,2.914750021696091,2.9969166656335195,-1.3854910877309585,26.28870450508475,-2.741705996688414,64.14311266084312,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-10-18,3.6500000953674316,3.890000104904175,3.5999999046325684,3.799999952316284,60111,0.0,0.0,3.7210000276565554,2.9370000183582308,2.9985833326975504,2.12308315164088,26.693905495328423,-2.0537469700373063,67.87075085664915,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-10-19,3.799999952316284,3.869999885559082,3.7200000286102295,3.740000009536743,36027,0.0,0.0,3.725000023841858,2.961000019311905,2.9994999984900157,0.40268417715108357,25.802093871904,-1.2835465643437982,65.29086437394955,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-10-20,3.680000066757202,3.9800000190734863,3.619999885559082,3.9600000381469727,38626,0.0,0.0,3.7460000276565553,2.987250018119812,3.0033333321412403,5.712760515495585,25.399615195727876,-0.5355154504266036,69.82071130752794,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-10-23,3.9800000190734863,4.599999904632568,3.9000000953674316,4.429999828338623,186426,0.0,0.0,3.809000015258789,3.023250013589859,3.011499996980031,16.303486757472285,25.990242227301508,0.39017156306196066,76.78982752132448,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-10-24,4.449999809265137,5.0,4.400000095367432,4.650000095367432,205045,0.0,0.0,3.8860000133514405,3.0705000162124634,3.020999997854233,19.66032113718618,26.559192080543166,1.6385308968351424,79.20993563817618,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-10-25,4.650000095367432,4.989999771118164,4.559999942779541,4.75,136194,0.0,0.0,3.9940000057220457,3.119500017166138,3.032166663805644,18.928392418499325,28.033338154950037,2.8802293225822417,80.21954581824123,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-10-26,4.650000095367432,5.519999980926514,4.550000190734863,5.179999828338623,259951,0.0,0.0,4.150999999046325,3.180500012636185,3.0456666628519695,24.789203313146377,30.51406956624198,4.427055377687231,83.85111149661665,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-10-27,5.179999828338623,5.599999904632568,5.0,5.539999961853027,151953,0.0,0.0,4.33899998664856,3.2515000104904175,3.062666662534078,27.679188266882647,33.4461009580042,6.165651334712904,86.14459640891819,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-10-30,5.539999961853027,5.840000152587891,5.340000152587891,5.619999885559082,107602,0.0,0.0,4.5299999713897705,3.327250009775162,3.0799999952316286,24.061808411775942,36.14846969963295,8.027597887218146,86.60003366375936,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-10-31,5.619999885559082,6.300000190734863,5.539999961853027,6.199999809265137,189239,0.0,0.0,4.786999940872192,3.4160000026226043,3.1023333271344504,29.517440690327135,40.134658583050786,10.110669693184777,89.3367110173847,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-11-01,6.21999979019165,7.239999771118164,6.099999904632568,6.380000114440918,332942,0.0,0.0,5.044999957084656,3.512250006198883,3.126166661580404,26.46184675346789,43.64011525889595,12.350056360184537,90.01805298396756,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-11-02,6.239999771118164,6.400000095367432,5.21999979019165,5.699999809265137,265099,0.0,0.0,5.240999937057495,3.5922500014305117,3.1443333268165587,8.757868302233605,45.89741624247799,14.24520329298041,71.44557520925225,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-11-03,5.679999828338623,5.960000038146973,5.519999980926514,5.679999828338623,23042,0.0,0.0,5.41299991607666,3.6712499976158144,3.162083325783412,4.932568195114337,47.44296682579432,16.10225346311061,70.98170995115123,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-11-06,5.679999828338623,5.679999828338623,4.809999942779541,4.989999771118164,265388,0.0,0.0,5.468999910354614,3.733499991893768,3.1741666575272878,-8.758459445748853,46.4845298574793,17.621423028941003,57.18685978852055,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-11-07,4.900000095367432,5.480000019073486,4.900000095367432,5.21999979019165,70065,0.0,0.0,5.525999879837036,3.8014999866485595,3.1889166553815205,-5.537461026047099,45.36366958424779,19.20976298434334,59.978907881283185,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-11-08,5.059999942779541,5.400000095367432,5.059999942779541,5.139999866485596,24606,0.0,0.0,5.5649998664855955,3.8674999833106996,3.204166654745738,-7.6370172542051735,43.89139988364741,20.702210591402572,58.54866693594222,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-11-09,5.079999923706055,5.380000114440918,4.28000020980835,4.619999885559082,91851,0.0,0.0,5.508999872207641,3.9214999794960024,3.2149166544278462,-16.137230119272218,40.48195591003591,21.978278164536295,50.17366497953736,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-11-10,4.610000133514404,5.400000095367432,4.610000133514404,4.789999961853027,76565,0.0,0.0,5.433999872207641,3.9802499771118165,3.227833320697149,-11.851305217145313,36.52408525734626,23.310269820628793,52.56267812947373,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-11-13,4.800000190734863,4.880000114440918,4.300000190734863,4.5,54543,0.0,0.0,5.321999883651733,4.034499979019165,3.237833321094513,-15.44531945926521,31.91225458738446,24.60493110421594,48.30759075122152,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-11-14,4.5,5.400000095367432,4.5,5.119999885559082,45424,0.0,0.0,5.213999891281128,4.102999973297119,3.25308332045873,-1.8028386590347545,27.0777461665744,26.126495054499216,56.42861354266483,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-11-15,5.099999904632568,5.099999904632568,4.559999942779541,4.739999771118164,54868,0.0,0.0,5.049999856948853,4.163249969482422,3.265083318948746,-6.138615734892061,21.299463014868465,27.508230657429518,51.12696681806662,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-11-16,4.840000152587891,5.0,4.699999809265137,4.900000095367432,76450,0.0,0.0,4.969999885559082,4.226249969005584,3.2784999867280322,-1.4084465151607477,17.598341839881705,28.908036788598977,53.1239933346093,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-11-17,4.900000095367432,4.980000019073486,4.699999809265137,4.900000095367432,32451,0.0,0.0,4.891999912261963,4.2867499709129335,3.2944166541099547,0.16353604351904918,14.119086614704793,30.121670116164324,53.1239933346093,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-11-20,4.71999979019165,4.71999979019165,4.5,4.550000190734863,21430,0.0,0.0,4.847999954223633,4.325999975204468,3.3073333223660786,-6.14685986597729,12.0665737866652,30.800241570741687,48.13417743264391,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-11-21,4.5,4.739999771118164,4.489999771118164,4.570000171661377,37266,0.0,0.0,4.7829999923706055,4.3757499814033505,3.3204166571299236,-4.453268263620864,9.306976237171702,31.783159562439607,48.432247490510484,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-11-22,4.739999771118164,4.960000038146973,4.599999904632568,4.960000038146973,13285,0.0,0.0,4.7650000095367435,4.434499984979629,3.337583323319753,4.092340571247704,7.45292650076833,32.8655963132276,53.98554481666693,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-11-23,4.75,4.929999828338623,4.699999809265137,4.920000076293945,16990,0.0,0.0,4.79500002861023,4.489499986171722,3.3528333246707915,2.606883147818152,6.8047676440469855,33.90167513359877,53.35095265498034,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-11-24,4.75,4.840000152587891,4.599999904632568,4.730000019073486,17732,0.0,0.0,4.789000034332275,4.5354999840259556,3.365583324432373,-1.2319902868201873,5.589241565409497,34.761185411770974,50.324883616273766,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-11-27,4.639999866485596,5.079999923706055,4.639999866485596,4.900000095367432,43413,0.0,0.0,4.829000043869018,4.57824998497963,3.379583324988683,1.4702847557136836,5.47698486784365,35.46788301173077,52.8991049279579,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-11-28,4.940000057220459,5.039999961853027,4.710000038146973,4.760000228881836,41723,0.0,0.0,4.793000078201294,4.618749988079071,3.3929999927679697,-0.6885009134371173,3.7726677255092698,36.125847271551244,50.574742447202794,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-11-29,4.760000228881836,5.019999980926514,4.710000038146973,4.960000038146973,32966,0.0,0.0,4.815000104904175,4.657749986648559,3.4084999938805898,3.0114211855387643,3.3760961560060734,36.65101936367304,53.704299248518154,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-11-30,5.0,5.039999961853027,4.800000190734863,4.96999979019165,21773,0.0,0.0,4.8220000743865965,4.689499980211258,3.4257499913374585,3.069259923723266,2.8254631567216664,36.889731943936,53.86160359634356,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-12-01,5.059999942779541,5.059999942779541,4.889999866485596,5.059999942779541,23083,0.0,0.0,4.838000059127808,4.722249978780747,3.442999990781148,4.588670544409944,2.451163764459303,37.155097049807495,55.332658451246544,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-12-04,5.119999885559082,5.119999885559082,4.860000133514404,5.099999904632568,21520,0.0,0.0,4.8930000305175785,4.754749977588654,3.46058332324028,4.230530815939798,2.9076198239773134,37.39735569021337,56.0040564197798,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-12-05,5.099999904632568,5.099999904632568,4.630000114440918,4.699999809265137,49810,0.0,0.0,4.905999994277954,4.775249969959259,3.4754166543483733,-4.198943849430953,2.738077066985669,37.40079089465604,48.20151926408856,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-12-06,4.96999979019165,5.0,4.730000019073486,4.849999904632568,23600,0.0,0.0,4.894999980926514,4.804749965667725,3.4921666542689005,-0.9193069758792481,1.8783498809234471,37.58650263137625,50.96067953635457,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-12-07,4.75,4.820000171661377,4.550000190734863,4.71999979019165,34970,0.0,0.0,4.874999952316284,4.83249996304512,3.50783331990242,-3.179490536220168,0.8794617609139778,37.76310110366218,48.54710812041756,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-12-08,4.71999979019165,4.889999866485596,4.570000171661377,4.710000038146973,17410,0.0,0.0,4.872999954223633,4.858749961853027,3.522749986251195,-3.3449603449181473,0.29328515528654603,37.9249160688682,48.357386012971645,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-12-11,4.710000038146973,4.769999980926514,4.449999809265137,4.659999847412109,46871,0.0,0.0,4.848999929428101,4.882499957084656,3.5382499853769938,-3.897712616347313,-0.6861244844036464,37.9919445280358,47.360741720880554,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-12-12,4.75,4.78000020980835,4.570000171661377,4.730000019073486,18909,0.0,0.0,4.845999908447266,4.90999995470047,3.553666651248932,-2.393724547364832,-1.3034632758384261,38.16715062384527,48.94713057915771,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-12-13,4.760000228881836,4.800000190734863,4.599999904632568,4.739999771118164,17882,0.0,0.0,4.823999881744385,4.933499950170517,3.5694999833901724,-1.741295868271162,-2.2195210202109634,38.2126340699649,49.18273637794424,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-12-14,4.739999771118164,4.829999923706055,4.699999809265137,4.809999942779541,4637,0.0,0.0,4.807999897003174,4.960249948501587,3.5854999820391336,0.041598290749007574,-3.0694028139530634,38.341932041528274,50.891253078630434,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-12-15,4.829999923706055,4.900000095367432,4.699999809265137,4.849999904632568,34741,0.0,0.0,4.786999893188477,4.982499945163727,3.6021666487058,1.3160646093545076,-3.923734152069834,38.31952907991799,51.88670032722367,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-12-18,4.900000095367432,5.0,4.71999979019165,4.760000228881836,38466,0.0,0.0,4.752999925613404,4.990749955177307,3.6176666498184202,0.1472817878811313,-4.763813689308682,37.95494273713155,49.4575305091009,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-12-19,4.800000190734863,4.909999847412109,4.75,4.909999847412109,26519,0.0,0.0,4.773999929428101,4.997249948978424,3.6348333160082498,2.8487624632265307,-4.467457538239843,37.48223135762306,53.37540724395316,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-12-20,4.909999847412109,4.909999847412109,4.760000228881836,4.909999847412109,3343,0.0,0.0,4.779999923706055,5.0012499451637265,3.651666647195816,2.719663719267641,-4.423894504045398,36.958009269665425,53.37540724395316,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-12-21,4.909999847412109,4.909999847412109,4.800000190734863,4.909999847412109,4845,0.0,0.0,4.798999929428101,4.994499945640564,3.6675833125909167,2.312980196214263,-3.914306103519033,36.17959075378889,53.37540724395316,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-12-22,4.909999847412109,4.909999847412109,4.75,4.909999847412109,23416,0.0,0.0,4.818999910354615,4.978749942779541,3.684249977270762,1.888357309614442,-3.2086373941435826,35.1360513943119,53.37540724395316,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-12-27,4.909999847412109,4.929999828338623,4.760000228881836,4.849999904632568,55721,0.0,0.0,4.83799991607666,4.959499943256378,3.7004166424274443,0.24803614642556382,-2.4498443103104868,34.02544692921349,51.238478926107426,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-12-28,4.920000076293945,4.920000076293945,4.75,4.809999942779541,40008,0.0,0.0,4.845999908447266,4.924749946594238,3.716666642824809,-0.7428800319408124,-1.5990667343716107,32.50448371800274,49.806847474600126,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2023-12-29,4.809999942779541,4.809999942779541,4.559999942779541,4.559999942779541,37717,0.0,0.0,4.827999925613403,4.879249942302704,3.731416642665863,-5.550952505447942,-1.0503667017540452,30.761327655353604,41.92278216102614,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-01-02,4.590000152587891,4.829999923706055,4.590000152587891,4.829999923706055,33787,0.0,0.0,4.829999923706055,4.857499945163727,3.747999976078669,0.0,-0.5661352911604619,29.602454006573065,50.95271534389282,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-01-03,4.679999828338623,5.360000133514404,4.679999828338623,5.0,83767,0.0,0.0,4.844999933242798,4.840499949455261,3.766333309809367,3.1991758285424576,0.09296526876409153,28.52022248929061,55.630432857268424,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-01-04,4.989999771118164,5.119999885559082,4.820000171661377,5.059999942779541,26448,0.0,0.0,4.874999904632569,4.842249953746796,3.7859166423479715,3.794872651611177,0.6763374711879903,27.901652656137237,57.18255596361759,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-01-05,5.139999866485596,5.519999980926514,5.119999885559082,5.360000133514404,22304,0.0,0.0,4.9199999332427975,4.845749962329864,3.805166643857956,8.94309362280012,1.5322699580073538,27.3465899358586,63.96939967880234,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-01-08,5.360000133514404,5.599999904632568,5.199999809265137,5.400000095367432,33642,0.0,0.0,4.96899995803833,4.85224996805191,3.825249977906545,8.673780256968506,2.406100072237055,26.84791833414804,64.77120264202159,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-01-09,5.400000095367432,5.539999961853027,5.159999847412109,5.300000190734863,42096,0.0,0.0,5.007999992370605,4.869249975681305,3.845583313703537,5.830674896347911,2.849515169323108,26.619281874091367,61.10992549319353,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-01-10,5.440000057220459,5.599999904632568,5.119999885559082,5.519999980926514,42972,0.0,0.0,5.069000005722046,4.887499976158142,3.86783331433932,8.89721788706579,3.7135556102155425,26.36273538568958,65.70309934499818,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-01-11,5.519999980926514,5.519999980926514,5.300000190734863,5.460000038146973,21202,0.0,0.0,5.130000019073487,4.911499977111816,3.8895833154519397,6.432748885897397,4.448743621702268,26.27316549822093,63.5003578441175,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-01-12,5.340000152587891,5.679999828338623,5.340000152587891,5.659999847412109,26719,0.0,0.0,5.215000009536743,4.9249999761581424,3.9129999816417693,8.533074536176207,5.888325579339829,25.862509564637676,67.4211744627589,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-01-15,5.400000095367432,5.619999885559082,5.340000152587891,5.5,32001,0.0,0.0,5.309000015258789,4.943999981880188,3.9354999820391336,3.597664045813731,7.382686786333544,25.62571476162252,61.71008770446465,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-01-16,5.599999904632568,5.599999904632568,5.199999809265137,5.380000114440918,19949,0.0,0.0,5.364000034332276,4.955999982357025,3.956999983390172,0.29828635358377903,8.232446598621847,25.246398866824276,57.75839208597048,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-01-17,5.480000019073486,5.639999866485596,5.28000020980835,5.639999866485596,25129,0.0,0.0,5.428000020980835,4.974499976634979,3.980249983072281,3.905671420142197,9.116495054295443,24.979586653882848,63.24958118666686,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-01-18,3.5799999237060547,3.640000104904175,1.9199999570846558,2.0199999809265137,1180324,0.0,0.0,5.124000024795532,4.91124997138977,3.9730833152929943,-60.57767425543447,4.3318921790812235,23.613062743628646,21.446682827261824,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-01-19,2.0399999618530273,2.0399999618530273,1.8600000143051147,1.9149999618530273,256576,0.0,0.0,4.7795000076293945,4.844874966144562,3.9656249821186065,-59.933048251989504,-1.3493631718465362,22.171788507248667,21.01287271205723,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-01-22,1.9149999618530273,1.9149999618530273,1.8049999475479126,1.840000033378601,105174,0.0,0.0,4.4235000014305115,4.766874966025353,3.9577083160479862,-58.40397800873595,-7.203355805263531,20.445333141310645,20.69093210732602,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-01-23,1.840000033378601,1.909999966621399,1.8350000381469727,1.899999976158142,53974,0.0,0.0,4.0834999799728395,4.691374963521957,3.9503749827543895,-53.47128724191204,-12.95728839147761,18.757712470397102,21.724152042889415,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-01-24,1.899999976158142,1.899999976158142,1.8250000476837158,1.840000033378601,92330,0.0,0.0,3.715499985218048,4.619124963879585,3.9418749839067457,-50.47772733955161,-19.562687429495007,17.180909661970688,21.42358131228356,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-01-25,1.840000033378601,1.8949999809265137,1.840000033378601,1.850000023841858,43740,0.0,0.0,3.3544999837875364,4.542874962091446,3.93320831656456,-44.850200244954564,-26.15909502727775,15.50049212901584,21.61823039010774,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-01-26,1.8899999856948853,1.9049999713897705,1.8550000190734863,1.899999976158142,37120,0.0,0.0,2.9784999966621397,4.471374955773354,3.925208317240079,-36.20950215587108,-33.3873802550073,13.914335097437561,22.64998216702317,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-01-29,1.9900000095367432,1.9900000095367432,1.8200000524520874,1.840000033378601,19366,0.0,0.0,2.6125,4.393374955654144,3.9172083179155988,-29.569376712780816,-40.53546473109951,12.155765001334421,22.271131228364624,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-01-30,1.840000033378601,1.8650000095367432,1.809999942779541,1.8450000286102295,32339,0.0,0.0,2.258999991416931,4.315249961614609,3.9094999849796297,-18.326691650274196,-47.65077315308762,10.378564476119147,22.387633626630333,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-01-31,1.809999942779541,1.8450000286102295,1.7599999904632568,1.809999942779541,134329,0.0,0.0,1.8759999990463256,4.233999961614609,3.901499984661738,-3.5181266684614125,-55.692016626024596,8.522362636423253,22.137503863987362,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-02-01,1.815000057220459,1.875,1.7999999523162842,1.7999999523162842,14920,0.0,0.0,1.8539999961853026,4.151499962806701,3.8934999843438467,-2.912623731398395,-55.34144254377229,6.62642813664565,22.06166172709449,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-02-02,1.7899999618530273,1.8450000286102295,1.7100000381469727,1.7200000286102295,93864,0.0,0.0,1.834500002861023,4.076999968290329,3.885499984025955,-6.241481279488868,-55.00367875572214,4.928580235533832,21.42915998144116,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-02-05,1.7949999570846558,1.815000057220459,1.7100000381469727,1.774999976158142,55001,0.0,0.0,1.827999997138977,4.000124970078469,3.877708316842715,-2.89934469714365,-54.30142781006369,3.1569329932331573,23.06228774325963,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-02-06,1.7999999523162842,1.809999942779541,1.684999942779541,1.715000033378601,48241,0.0,0.0,1.8095000028610229,3.924999976158142,3.8689999838670093,-5.222435442553563,-53.89808881904268,1.447402236356733,22.512548585705858,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-02-07,1.75,1.7799999713897705,1.7050000429153442,1.7799999713897705,19076,0.0,0.0,1.80349999666214,3.851749974489212,3.860833317041397,-1.3030233055648728,-53.17712705635039,-0.23526896414025744,24.60916804200029,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-02-08,1.7799999713897705,1.7999999523162842,1.7100000381469727,1.784999966621399,27596,0.0,0.0,1.796999990940094,3.7798749774694445,3.8526249835888544,-0.6677809893820478,-52.45874528519058,-1.888323063607421,24.777775096074905,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-02-09,1.7999999523162842,1.809999942779541,1.6950000524520874,1.7450000047683716,73403,0.0,0.0,1.781499993801117,3.7052499771118166,3.8433333178361258,-2.0488346427027886,-51.91957344832729,-3.592801594477704,24.309386964729413,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-02-12,1.7450000047683716,1.784999966621399,1.7100000381469727,1.7649999856948853,37947,0.0,0.0,1.7739999890327454,3.6308749824762345,3.833791650334994,-0.5073282634441989,-51.14125389624712,-5.292845474297717,25.07206636897078,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-02-13,1.7649999856948853,1.7649999856948853,1.7000000476837158,1.7000000476837158,22297,0.0,0.0,1.759499990940094,3.553124985098839,3.8247916509707767,-3.3816393045042017,-50.48021112910136,-7.102783384370377,24.217972086501305,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-02-14,1.75,1.809999942779541,1.7050000429153442,1.7699999809265137,96564,0.0,0.0,1.7554999947547913,3.4761249870061874,3.8152916500965754,0.8259747203102489,-49.498363801161375,-8.889665435715846,27.098177345556877,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-02-15,1.7549999952316284,1.7699999809265137,1.7000000476837158,1.7000000476837158,44568,0.0,0.0,1.7455000042915345,3.3996249824762343,3.8045416504144667,-2.6067004580894437,-48.656101385037495,-10.642981603161598,26.032660183867492,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-02-16,1.7050000429153442,1.725000023841858,1.6699999570846558,1.725000023841858,31530,0.0,0.0,1.7460000038146972,3.319999986886978,3.795916650692622,-1.2027479912347145,-47.409638231599914,-12.537595200326802,27.134626240387988,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-02-19,1.75,1.7699999809265137,1.690000057220459,1.715000033378601,124847,0.0,0.0,1.7400000095367432,3.2401249915361405,3.7869583179553348,-1.4367802310988533,-46.298367683901894,-14.439908773921811,26.961597394351955,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-02-20,1.715000033378601,1.7799999713897705,1.7000000476837158,1.774999976158142,35430,0.0,0.0,1.7460000038146972,3.1617499947547913,3.778916651010513,1.6609377021812786,-44.77741735712068,-16.331840928290557,29.85192044929842,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-02-21,1.7949999570846558,1.8049999475479126,1.7100000381469727,1.8049999475479126,76438,0.0,0.0,1.7485000014305114,3.0841249972581863,3.771458316842715,3.231338065266028,-43.306448247559906,-18.224603371990373,31.31547431760049,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-02-22,1.7999999523162842,1.7999999523162842,1.715000033378601,1.7450000047683716,32606,0.0,0.0,1.7445000052452087,3.0064999997615813,3.7644166509310404,0.02866148017538413,-41.9757190958407,-20.13370786100434,29.96875732454454,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-02-23,1.7450000047683716,1.7450000047683716,1.5099999904632568,1.649999976158142,182134,0.0,0.0,1.7350000023841858,2.9275000005960465,3.7560833166042964,-4.899136951541165,-40.73441496051459,-22.059769343916848,27.921318861770644,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-02-26,1.649999976158142,1.649999976158142,1.5399999618530273,1.6150000095367432,138913,0.0,0.0,1.7200000047683717,2.8538750022649766,3.748458316922188,-6.104650868635818,-39.7310672890966,-23.865366479298146,27.18444827197527,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-02-27,1.6150000095367432,1.6399999856948853,1.534999966621399,1.559999942779541,85255,0.0,0.0,1.705999994277954,2.772125002741814,3.7406249831120175,-8.558033528025065,-38.45876385117526,-25.891394746673026,26.022249528116348,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-02-28,1.6549999713897705,1.690000057220459,1.5750000476837158,1.659999966621399,155391,0.0,0.0,1.6949999928474426,2.6886250019073485,3.7334583163261414,-2.0648983111349106,-36.95662311981084,-27.98566974351402,31.736630248477937,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-02-29,1.7000000476837158,1.7000000476837158,1.6349999904632568,1.6950000524520874,63049,0.0,0.0,1.6944999933242797,2.604500004649162,3.726749983429909,0.02951071878298962,-34.939528112900256,-30.113369122440716,33.66791101174485,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-03-01,1.6549999713897705,1.7000000476837158,1.6200000047683716,1.6799999475479126,72172,0.0,0.0,1.6899999856948853,2.5125,3.7199166496594747,-0.591718238557318,-32.736318977318,-32.458164076606465,33.23395117264869,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-03-04,1.6799999475479126,1.7549999952316284,1.6799999475479126,1.7549999952316284,77469,0.0,0.0,1.693999981880188,2.421374997496605,3.713708316286405,3.6009453367133926,-30.03975081796213,-34.79899897152111,37.56705519879642,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-03-05,1.7999999523162842,1.7999999523162842,1.7050000429153442,1.7100000381469727,35746,0.0,0.0,1.687499988079071,2.3316249936819076,3.707458316286405,1.3333363097391195,-27.625583331292397,-37.109879740539014,36.05507839866083,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-03-06,1.7599999904632568,1.7999999523162842,1.7100000381469727,1.75,165649,0.0,0.0,1.6819999933242797,2.2373749941587446,3.701708315809568,4.042806596052718,-24.82261589069411,-39.55831191228182,38.42731618463723,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-03-07,1.75,1.75,1.684999942779541,1.7300000190734863,58758,0.0,0.0,1.6804999947547912,2.1441249936819076,3.696708316604296,2.945553375376113,-21.62303971518825,-41.99907566276565,37.67472871787113,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-03-08,1.7300000190734863,1.9800000190734863,1.690000057220459,1.7450000047683716,175974,0.0,0.0,1.6899999976158142,2.0462499976158144,3.691416649023692,3.2544382976419666,-17.409896171781767,-44.5673519905425,38.64526320399671,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-03-11,1.7450000047683716,1.7450000047683716,1.6449999809265137,1.6699999570846558,52822,0.0,0.0,1.6954999923706056,1.9504999965429306,3.6859166493018467,-1.5039832144320027,-13.073571116343885,-47.082362893030236,35.65555137951151,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-03-12,1.6649999618530273,1.6649999618530273,1.5399999618530273,1.6150000095367432,85116,0.0,0.0,1.7009999990463256,1.8563749939203262,3.6795416484276453,-5.055848886407923,-8.369806498302205,-49.548743531314585,33.60254343526293,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-03-13,1.5750000476837158,1.6200000047683716,1.475000023841858,1.534999966621399,104846,0.0,0.0,1.6884999990463256,1.7537499964237213,3.6716666479905444,-9.090911016382849,-3.7205985750793813,-52.235587689216665,30.82254473595181,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-03-14,1.565000057220459,1.6200000047683716,1.4800000190734863,1.5399999618530273,120072,0.0,0.0,1.6729999899864196,1.741749995946884,3.6596666475137076,-7.949792524175203,-3.9471799121830466,-52.40686751810609,31.205624689888907,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-03-15,1.6150000095367432,1.6150000095367432,1.4950000047683716,1.534999966621399,5333,0.0,0.0,1.6584999918937684,1.7322499960660935,3.650958314538002,-7.446489350376795,-4.257468860719294,-52.55355315429573,31.0206296278526,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-03-18,1.534999966621399,1.5750000476837158,1.350000023841858,1.4700000286102295,143389,0.0,0.0,1.6299999952316284,1.7229999959468842,3.641458315650622,-9.815948901193854,-5.397562445387423,-52.68379186048613,28.643355903356195,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-03-19,1.4550000429153442,1.4850000143051147,1.375,1.399999976158142,79194,0.0,0.0,1.5989999890327453,1.710499995946884,3.6304583152135215,-12.445279189462708,-6.518562243691531,-52.88473665214683,26.30536399516953,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-03-20,1.399999976158142,1.440000057220459,1.0,1.409999966621399,120322,0.0,0.0,1.5649999856948853,1.6997499942779541,3.6181249807278317,-9.904154663916106,-7.927636948768459,-53.021247100866375,27.219311326159428,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-03-21,1.4049999713897705,1.440000057220459,1.3450000286102295,1.399999976158142,88468,0.0,0.0,1.531999981403351,1.6884999930858613,3.6032083133856454,-8.616188436522922,-9.268582311125439,-53.13898486487134,26.86056691110366,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-03-22,1.4450000524520874,1.4450000524520874,1.2799999713897705,1.4249999523162842,29867,0.0,0.0,1.4999999761581422,1.6766249924898147,3.588916645447413,-5.000001668930086,-10.534557049002444,-53.283256254596076,29.366912190727746,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-03-25,1.4299999475479126,1.4500000476837158,1.4299999475479126,1.4500000476837158,13991,0.0,0.0,1.477999985218048,1.6668749928474427,3.572666645050049,-1.894447754693412,-11.331084120876302,-53.34367411085196,31.880798390141678,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-03-26,1.4500000476837158,1.5049999952316284,1.4500000476837158,1.5049999952316284,20897,0.0,0.0,1.4669999837875367,1.6583749920129776,3.5543749779462814,2.5903211904598895,-11.53991160908336,-53.3427113823768,37.1780896630785,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-03-27,1.5049999952316284,1.5049999952316284,1.3949999809265137,1.5,46702,0.0,0.0,1.4634999871253966,1.6506249934434891,3.5356249779462816,2.4940220837512,-11.336615346391754,-53.31447753256121,36.897178203569055,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-03-28,1.4299999475479126,1.475000023841858,1.4249999523162842,1.4450000524520874,21301,0.0,0.0,1.4539999961853027,1.6417499959468842,3.5159999787807465,-0.6189782501256863,-11.435967731085396,-53.30631382665143,33.865921915036125,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-04-02,1.4450000524520874,1.5049999952316284,1.4450000524520874,1.5049999952316284,54444,0.0,0.0,1.4509999990463256,1.6363749951124191,3.496208311120669,3.721571069661923,-11.328393346254858,-53.19572378146146,39.68712533670796,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-04-03,1.590000033378601,1.590000033378601,1.3899999856948853,1.4450000524520874,158497,0.0,0.0,1.4485000014305114,1.6281249970197678,3.4776666442553203,-0.2416257490484984,-11.032629307826754,-53.18340819959754,36.250832692925385,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-04-04,1.4450000524520874,1.4950000047683716,1.25,1.3049999475479126,147061,0.0,0.0,1.4389999985694886,1.6178749948740005,3.4584583113590877,-9.31202579254938,-11.056169164567791,-53.21976299207678,29.773054166938877,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-04-05,1.3550000190734863,1.3550000190734863,1.2599999904632568,1.2799999713897705,210535,0.0,0.0,1.4259999990463257,1.6053749948740006,3.43862497707208,-10.238431118807606,-11.173401628929279,-53.31346088688784,28.783922728889408,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-04-08,1.3350000381469727,1.3350000381469727,1.2050000429153442,1.225000023841858,226208,0.0,0.0,1.4085000038146973,1.591374996304512,3.417916643619537,-13.028042561296344,-11.491634147481689,-53.440204597287575,26.683616266618003,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-04-09,1.274999976158142,1.274999976158142,1.2100000381469727,1.2100000381469727,52062,0.0,0.0,1.3870000123977662,1.577999997138977,3.3977499763170878,-12.761353472867393,-12.103928079056216,-53.557501048107916,26.123753584982296,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-04-10,1.274999976158142,1.274999976158142,1.2400000095367432,1.2400000095367432,94155,0.0,0.0,1.3660000085830688,1.5648749977350236,3.376416643460592,-9.22401158525786,-12.708682127313903,-53.65278746727371,29.317943185025342,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-04-11,1.284999966621399,1.284999966621399,1.2400000095367432,1.2400000095367432,13768,0.0,0.0,1.3395000100135803,1.5533749967813493,3.3555833101272583,-7.428144810228736,-13.768406676489958,-53.7077505394304,29.317943185025342,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-04-12,1.2999999523162842,1.315000057220459,1.1699999570846558,1.2200000286102295,233945,0.0,0.0,1.3115000128746033,1.539624997973442,3.332749976714452,-6.9767429177389095,-14.816918756132965,-53.80316529200726,28.369554225640186,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-04-15,1.2200000286102295,1.274999976158142,1.1549999713897705,1.1549999713897705,98821,0.0,0.0,1.2825000047683717,1.5259999960660935,3.3054583112398785,-9.941523033493365,-15.956749143213985,-53.833936102685556,25.4842376072871,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-04-16,1.2450000047683716,1.2450000047683716,1.1950000524520874,1.1950000524520874,11558,0.0,0.0,1.2515000104904175,1.5127499967813491,3.2766666442155836,-4.514579110246255,-17.26987187881597,-53.83265491923444,30.189598280649392,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-04-17,1.2699999809265137,1.2699999809265137,1.1050000190734863,1.1449999809265137,77431,0.0,0.0,1.22150000333786,1.498499995470047,3.2466249773899714,-6.2627934672372545,-18.4851513493197,-53.84437667097842,27.824412748452218,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-04-18,1.25,1.25,1.1299999952316284,1.1749999523162842,118001,0.0,0.0,1.2085000038146974,1.4834999948740006,3.2132499784231188,-2.772035696538552,-18.5372424677804,-53.83179009303165,31.30206734930441,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-04-19,1.225000023841858,1.225000023841858,1.184999942779541,1.1950000524520874,15816,0.0,0.0,1.2000000119209289,1.468249997496605,3.177041645844777,-0.4166632849309441,-18.27004842724656,-53.78562319392586,33.59909453001042,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-04-22,1.1950000524520874,1.2300000190734863,1.1649999618530273,1.1950000524520874,28171,0.0,0.0,1.197000014781952,1.4544999986886977,3.1401666472355525,-0.16708122850181115,-17.703677149459917,-53.68080226031419,33.59909453001043,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-04-23,1.1950000524520874,1.2100000381469727,1.184999942779541,1.2000000476837158,8603,0.0,0.0,1.1960000157356263,1.4432500004768372,3.0984999825557074,0.33445082737973064,-17.13147304067359,-53.42100988858439,34.23664302863443,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-04-24,1.184999942779541,1.184999942779541,1.0,1.0850000381469727,216055,0.0,0.0,1.1805000185966492,1.4300000011920928,3.0543749819199246,-8.089790677276287,-17.447551215905776,-53.18191087679677,27.65877523606899,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-04-25,1.090000033378601,1.090000033378601,0.8999999761581421,0.9399999976158142,893352,0.0,0.0,1.1505000174045563,1.4145000025629997,3.014708316822847,-18.296394315891863,-18.663837729239255,-53.08003780432998,21.936003713428107,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-04-26,0.9399999976158142,1.034999966621399,0.9100000262260437,0.949999988079071,422202,0.0,0.0,1.1235000133514403,1.3967500030994415,2.9752916514873506,-15.442814704987192,-19.563271103751497,-53.05502227315413,23.117459124287038,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-04-29,0.9520000219345093,0.9879999756813049,0.9319999814033508,0.9359999895095825,44172,0.0,0.0,1.1016000151634215,1.377775001525879,2.941508319973946,-15.032681860418492,-20.044999078702617,-53.16093474323124,22.601730383938715,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-04-30,0.9359999895095825,0.949999988079071,0.9279999732971191,0.9399999976158142,10744,0.0,0.0,1.0761000096797944,1.3592750027775764,2.9058416550358137,-12.64752447167789,-20.832796345046823,-53.2226747310213,23.129396358951865,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-05-02,0.949999988079071,1.0299999713897705,0.949999988079071,0.949999988079071,91875,0.0,0.0,1.0566000103950501,1.3391500025987626,2.870924989382426,-10.08896661624323,-21.099204096284527,-53.354754737537334,24.514915039105517,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-05-03,0.9520000219345093,0.9639999866485596,0.9300000071525574,0.9300000071525574,72443,0.0,0.0,1.0321000158786773,1.3196500018239021,2.8401749903957048,-9.89245297503432,-21.78986743059137,-53.536313562142766,23.598786435351897,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-05-06,0.9300000071525574,0.9300000071525574,0.9100000262260437,0.9179999828338623,42876,0.0,0.0,1.0044000089168548,1.2988500013947486,2.8079083239038787,-8.602153058139283,-22.67005367530535,-53.74314786784288,23.042381915525866,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-05-07,0.9200000166893005,0.9200000166893005,0.8899999856948853,0.9079999923706055,214021,0.0,0.0,0.9757000029087066,1.2783000007271768,2.777974990506967,-6.938609238113905,-23.672064276486925,-53.98446691941265,22.564921954765666,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-05-08,0.9459999799728394,0.9480000138282776,0.8880000114440918,0.9480000138282776,80142,0.0,0.0,0.9504999995231629,1.2583750009536743,2.7432083249092103,-0.2630179585628054,-24.466077377346554,-54.127618032971604,28.910354850571096,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-05-10,0.9419999718666077,0.9879999756813049,0.9399999976158142,0.9399999976158142,20811,0.0,0.0,0.935999995470047,1.2401250019669532,2.711541660130024,0.42735065866730965,-24.523738011453343,-54.26494749457448,28.408943768216147,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-05-13,0.9679999947547913,0.9679999947547913,0.8980000019073486,0.906000018119812,59257,0.0,0.0,0.9325999975204468,1.22240000218153,2.6782583261529607,-2.852238845309621,-23.70746107198117,-54.35839813341007,26.319678620012112,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-05-14,0.8880000114440918,0.9340000152587891,0.8880000114440918,0.8980000019073486,112062,0.0,0.0,0.9273999989032745,1.2064750030636788,2.6449083253741263,-3.1701527960635927,-23.13143690932107,-54.38499733660821,25.838177561381826,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-05-15,0.8980000019073486,0.8999999761581421,0.8519999980926514,0.8519999980926514,81514,0.0,0.0,0.9189999997615814,1.1892750039696693,2.614091657102108,-7.290533371742333,-22.726030842819334,-54.5052293503718,23.20897357355267,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-05-16,0.8999999761581421,1.0499999523162842,0.8619999885559082,0.9800000190734863,746476,0.0,0.0,0.9230000019073487,1.1754000052809714,2.5841749891638757,6.175516473277252,-21.473541112779582,-54.515463921377915,41.153116766962675,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-05-17,0.9800000190734863,1.065000057220459,0.9200000166893005,1.065000057220459,609025,0.0,0.0,0.9345000088214874,1.1652750059962274,2.551716655989488,13.964692045701232,-19.80433768743231,-54.33368343381508,49.57903383263751,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-05-20,1.065000057220459,1.0750000476837158,0.972000002861023,0.9980000257492065,448415,0.0,0.0,0.9413000106811523,1.155225007236004,2.5190333222349484,6.0235859369665175,-18.518037197505745,-54.140145863133725,44.20604491930401,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-05-21,1.0299999713897705,1.0299999713897705,0.9800000190734863,0.984000027179718,257257,0.0,0.0,0.947900015115738,1.1445750087499618,2.4878166556358337,3.8084198215327882,-17.183233263936174,-53.99279098171997,43.153663376319905,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-05-22,0.9980000257492065,0.9980000257492065,0.9419999718666077,0.9559999704360962,161266,0.0,0.0,0.952700012922287,1.1334750086069107,2.4549499879280727,0.3463794971186133,-15.948741199579155,-53.828997976307434,41.04887505506399,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-05-23,0.9980000257492065,0.9980000257492065,0.9399999976158142,0.9399999976158142,80830,0.0,0.0,0.9519000113010406,1.121350009739399,2.4231166526675225,-1.2501327391478527,-15.11124956227881,-53.72282186641964,39.85270325916805,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-05-24,0.921999990940094,0.9639999866485596,0.9179999828338623,0.9319999814033508,157035,0.0,0.0,0.9511000096797944,1.10840000808239,2.3895499855279922,-2.008203982972717,-14.19162732367132,-53.61469670878305,39.237037761097774,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-05-27,0.9700000286102295,1.024999976158142,0.9340000152587891,0.9399999976158142,1019042,0.0,0.0,0.9545000076293946,1.0942750081419945,2.355966653923194,-1.5191209950424969,-12.773297340485598,-53.55303495829238,40.23140039172497,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-05-28,0.9819999933242798,0.9819999933242798,0.9399999976158142,0.9539999961853027,213415,0.0,0.0,0.9601000070571899,1.080625008046627,2.321749987701575,-0.635351612024705,-11.15326779335804,-53.45644389918158,42.019571545148075,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-05-29,0.9559999704360962,0.9860000014305115,0.9380000233650208,0.9440000057220459,115801,0.0,0.0,0.9693000078201294,1.068100006878376,2.287116655210654,-2.6101312177827127,-9.25007007040464,-53.299277304244065,41.074287514836136,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-05-30,0.9440000057220459,0.9940000176429749,0.9259999990463257,0.9399999976158142,233870,0.0,0.0,0.9653000056743621,1.0539750069379807,2.25578332344691,-2.6209476753160534,-8.413387478820598,-53.27676217911422,40.680067801086906,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-05-31,0.9480000138282776,1.059999942779541,0.921999990940094,0.972000002861023,343826,0.0,0.0,0.9560000002384186,1.042150005698204,2.2234666575988133,1.6736404412776253,-8.26656479285513,-53.1294970339851,45.210498677864436,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-06-03,0.9700000286102295,1.1200000047683716,0.9480000138282776,1.1200000047683716,1942516,0.0,0.0,0.9681999981403351,1.0375250071287154,2.1934666593869525,15.678579520719433,-6.68176752483614,-52.69930351169818,60.30883420691582,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-06-04,1.1050000190734863,1.2599999904632568,1.059999942779541,1.0950000286102295,975097,0.0,0.0,0.9792999982833862,1.032900008559227,2.1633416593074797,11.814564538921038,-5.189273872754293,-52.25442064986282,57.42989620109303,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-06-05,1.100000023841858,1.2050000429153442,1.100000023841858,1.1799999475479126,840632,0.0,0.0,1.0016999959945678,1.0317750066518783,2.1343416601419447,17.799735675980944,-2.9148807117265028,-51.65839537690231,63.763628249783466,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-06-07,1.1749999523162842,1.2799999713897705,1.1150000095367432,1.2799999713897705,636062,0.0,0.0,1.0356999933719635,1.0335250049829483,2.1055916597445807,23.587909585905404,0.2104437123948522,-50.91522137258464,69.51094592925863,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-06-10,1.2899999618530273,1.3550000190734863,1.2649999856948853,1.309999942779541,1056799,0.0,0.0,1.0734999895095825,1.0352750033140183,2.077008327841759,22.030736430468075,3.6922543356308375,-50.15547172168618,70.99711141552984,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-06-11,1.3250000476837158,1.3650000095367432,1.2400000095367432,1.350000023841858,897510,0.0,0.0,1.114499992132187,1.038025003671646,2.0481749951839445,21.130554811321982,7.367355139812403,-49.31951585619167,72.89429207811821,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-06-12,1.3700000047683716,1.3949999809265137,1.2799999713897705,1.2799999713897705,267758,0.0,0.0,1.1470999896526337,1.0395250022411346,2.0184249957402547,11.58573646028728,10.348475234321041,-48.49821001845599,64.89419163934684,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-06-13,1.309999942779541,1.3450000286102295,1.3049999475479126,1.3200000524520874,127094,0.0,0.0,1.1846999943256378,1.0436500042676926,1.9897583276033401,11.420617774499608,13.515066303948995,-47.54890632749521,67.11517182110698,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-06-14,1.3450000286102295,1.3450000286102295,1.2699999809265137,1.3049999475479126,256583,0.0,0.0,1.2211999893188477,1.0464000016450883,1.9597166617711386,6.86209948919229,16.70489176213199,-46.604525947165214,65.44312722012612,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-06-17,1.3200000524520874,1.3949999809265137,1.190000057220459,1.3049999475479126,288305,0.0,0.0,1.2544999837875366,1.0504000008106231,1.9296749959389368,4.0255053338389475,19.430691433682764,-45.56596302376184,65.44312722012612,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-06-18,1.3049999475479126,1.475000023841858,1.284999966621399,1.4249999523162842,609031,0.0,0.0,1.2849999785423278,1.0566500008106232,1.9006333301464717,10.894939775233993,21.610748834195135,-44.405373511512984,71.93109829334537,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-06-19,1.4450000524520874,1.4950000047683716,1.3550000190734863,1.375,639902,0.0,0.0,1.3129999756813049,1.061149999499321,1.871174998084704,4.722012602210736,23.733682919550812,-43.28964417622659,66.34206773260986,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-06-20,1.3799999952316284,1.4700000286102295,1.2949999570846558,1.440000057220459,514186,0.0,0.0,1.3389999866485596,1.0672749996185302,1.842758332689603,7.542947840103928,25.459697559406003,-42.08274733123653,69.644171492541,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-06-24,1.440000057220459,1.5499999523162842,1.399999976158142,1.5199999809265137,359930,0.0,0.0,1.3629999876022338,1.0752749979496001,1.815341666340828,11.518708345733115,26.758270228665715,-40.7673487648733,73.1372921685865,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-06-25,1.5149999856948853,1.5149999856948853,1.4149999618530273,1.4800000190734863,305054,0.0,0.0,1.3799999952316284,1.085149997472763,1.7896750003099442,7.246378564303781,27.171358655075345,-39.366086172917896,68.86996400112207,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-06-26,1.4850000143051147,1.4850000143051147,1.3799999952316284,1.409999966621399,223215,0.0,0.0,1.3859999895095825,1.0968999966979027,1.761175000667572,1.7316000933238478,26.356093872001424,-37.71771707626308,62.0471649608052,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-06-27,1.4049999713897705,1.4049999713897705,1.3300000429153442,1.399999976158142,235366,0.0,0.0,1.3979999899864197,1.1081499963998795,1.73117500046889,0.1430605283296029,26.156205795983855,-35.98856290671154,61.11568965818532,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-06-28,1.3949999809265137,1.3949999809265137,1.2200000286102295,1.2899999618530273,467508,0.0,0.0,1.3949999809265137,1.1169999957084655,1.6997583339611688,-7.526883190618305,24.888091878794018,-34.28477605370085,51.887978493858974,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-07-01,1.284999966621399,1.3450000286102295,1.2050000429153442,1.2100000381469727,294714,0.0,0.0,1.3854999899864198,1.1237499967217446,1.665174999833107,-12.66690386920662,23.29254674333832,-32.51460075761568,46.40080937195181,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-07-02,1.2100000381469727,1.3550000190734863,1.2050000429153442,1.3450000286102295,216038,0.0,0.0,1.3894999980926515,1.1336249977350235,1.6313833326101304,-3.202588668118495,22.571397143576124,-30.51142701566767,55.04106277050545,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-07-03,1.3250000476837158,1.3250000476837158,1.25,1.2899999618530273,151624,0.0,0.0,1.3759999990463256,1.1426249966025352,1.597966664036115,-6.250002707333064,20.424461493289947,-28.49506674209874,51.4053408930952,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-07-04,1.2949999570846558,1.3300000429153442,1.2699999809265137,1.315000057220459,210452,0.0,0.0,1.3700000047683716,1.1525499984622,1.5629249980052313,-4.014594697553417,18.86686101221692,-26.2568581388611,52.92741236912276,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-07-05,1.315000057220459,1.315000057220459,1.25,1.2949999570846558,239491,0.0,0.0,1.3554999947547912,1.1622249975800514,1.5282166639963786,-4.463300472463658,16.629740160224657,-23.9489383304614,51.536696930325675,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-07-08,1.2949999570846558,1.6950000524520874,1.2899999618530273,1.590000033378601,1726162,0.0,0.0,1.3625,1.1782749980688094,1.4942999988794328,16.697250156227597,15.635144786500184,-21.1486984573117,65.80784076072598,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-07-09,1.5499999523162842,1.715000033378601,1.5149999856948853,1.649999976158142,1087149,0.0,0.0,1.3794999957084655,1.1960249975323678,1.4622166653474171,19.608552467646568,15.340398282196634,-18.20466652606529,67.87960369476312,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-07-10,1.649999976158142,1.7999999523162842,1.6100000143051147,1.6399999856948853,479744,0.0,0.0,1.4024999976158141,1.2143749967217445,1.431049997607867,16.93404552462105,15.491508092798417,-15.140980486238414,67.14932502472627,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-07-11,1.6399999856948853,1.6950000524520874,1.4950000047683716,1.5449999570846558,516570,0.0,0.0,1.4169999957084656,1.2305499956011772,1.396924998362859,9.033165967808864,15.15176147038215,-11.910088441159465,60.491222021574025,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-07-12,1.5499999523162842,1.8049999475479126,1.5449999570846558,1.715000033378601,882593,0.0,0.0,1.459500002861023,1.2521249964833259,1.3943833321332932,17.5059972604815,16.561845419596548,-10.202240113722794,66.82949580175756,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-07-15,1.715000033378601,1.809999942779541,1.5700000524520874,1.7999999523162842,554169,0.0,0.0,1.518499994277954,1.272624994814396,1.393424998720487,18.538028258089213,19.32030256088262,-8.66928639984324,69.46704357166975,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-07-16,1.809999942779541,1.9299999475479126,1.7599999904632568,1.899999976158142,554070,0.0,0.0,1.5739999890327454,1.293499992787838,1.39392499824365,20.711562223436243,21.685349656659458,-7.204476968441477,72.26150097268152,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-07-17,1.9149999618530273,1.9199999570846558,1.809999942779541,1.909999966621399,285060,0.0,0.0,1.6359999895095825,1.3162999913096427,1.3940083314975102,16.748164967528663,24.287776366378054,-5.574453066890177,72.53223085219452,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-07-18,1.9149999618530273,1.9299999475479126,1.774999976158142,1.8899999856948853,869611,0.0,0.0,1.6934999823570251,1.338949990272522,1.3944249977668126,11.603188980514192,26.47970384706752,-3.9783428713006823,71.03887271348908,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-07-19,1.8600000143051147,2.0,1.784999966621399,1.9850000143051147,497127,0.0,0.0,1.762499988079071,1.3646749913692475,1.3955499976873398,12.62411504856485,29.151629452128052,-2.212389836928617,73.79842814266293,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-07-22,1.9900000095367432,2.0999999046325684,1.9500000476837158,2.009999990463257,529894,0.0,0.0,1.8044999837875366,1.3914249911904335,1.3964666644732158,11.388196648491407,29.687190844811322,-0.36103069346693784,74.48736515046042,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-07-23,2.049999952316284,2.140000104904175,1.940000057220459,1.9700000286102295,394062,0.0,0.0,1.8364999890327454,1.4173749923706054,1.3975499977668127,7.269264381961496,29.57050878689061,1.418553514040405,71.25890109603573,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-07-24,1.9700000286102295,2.140000104904175,1.875,2.0,483238,0.0,0.0,1.8724999904632569,1.4438749924302101,1.3988416641950607,6.809079315679975,29.68574151364869,3.219329920449791,72.23101963028529,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-07-25,2.0,2.0999999046325684,1.934999942779541,2.0799999237060547,521669,0.0,0.0,1.9259999871253968,1.472024990618229,1.401091664036115,7.9958430742518685,30.840169114011097,5.0627184789449675,74.689516766516,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-07-26,2.1500000953674316,2.1500000953674316,2.0299999713897705,2.1500000953674316,393766,0.0,0.0,1.9694999933242798,1.5021749928593635,1.4040083318948746,9.16476784234405,31.109890837376508,6.99188592648887,76.6384859599862,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-07-29,2.190000057220459,2.3399999141693115,2.069999933242798,2.3399999141693115,685995,0.0,0.0,2.0234999895095824,1.537174990773201,1.409174997607867,15.64121207316815,31.637582035585893,9.083328428521616,80.93067324097406,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-07-30,2.299999952316284,2.490000009536743,2.25,2.440000057220459,637118,0.0,0.0,2.0774999976158144,1.5738749921321868,1.4147166649500529,17.448859688118308,31.99904744666843,11.250191018832249,82.72922005393764,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-07-31,2.4600000381469727,2.5399999618530273,2.319999933242798,2.4000000953674316,363529,0.0,0.0,2.1265000104904175,1.6058749943971633,1.4204249987999598,12.861513450636618,32.420021353448746,13.055951264859475,79.49928887513448,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-08-01,2.4000000953674316,2.450000047683716,2.2300000190734863,2.319999933242798,312238,0.0,0.0,2.169500005245209,1.6364999920129777,1.4249249984820684,6.937078941402381,32.56950906407364,14.848149464448584,73.33266080595226,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-08-02,2.3299999237060547,2.4100000858306885,2.180000066757202,2.240000009536743,323331,0.0,0.0,2.1950000047683718,1.6629999935626985,1.428716665506363,2.0501141080006535,31.990379631087823,16.398165830402853,67.6790950997219,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-08-05,2.2300000190734863,2.2300000190734863,1.7000000476837158,1.9700000286102295,1262501,0.0,0.0,2.1910000085830688,1.68024999499321,1.430591665705045,-10.086717439848899,30.397263211533165,17.451403868281634,52.86561406285498,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-08-06,1.9600000381469727,2.2300000190734863,1.9550000429153442,2.0799999237060547,573491,0.0,0.0,2.2019999980926515,1.6994999945163727,1.4332166651884715,-5.540421184935146,29.567520164616145,18.57941899474664,56.99542754492586,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-08-07,2.069999933242798,2.2100000381469727,2.0,2.1600000858306885,236165,0.0,0.0,2.2180000066757204,1.7197499960660934,1.4370499988396963,-2.614964863411369,28.972235019588176,19.672245047469108,59.75705813703766,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-08-08,2.1600000858306885,2.2200000286102295,2.059999942779541,2.180000066757202,155596,0.0,0.0,2.228000020980835,1.7422499984502793,1.4404666662216186,-2.1543964888519986,27.8806154663583,20.950386378620355,60.44100072149044,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-08-09,2.180000066757202,2.7699999809265137,2.0999999046325684,2.3299999237060547,1589703,0.0,0.0,2.2460000038146974,1.7674999952316284,1.4457166651884714,3.7399786174838994,27.072136343647475,22.257703586837156,65.21582678411124,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-08-12,2.319999933242798,2.5799999237060547,2.240000009536743,2.549999952316284,633137,0.0,0.0,2.2670000076293944,1.7986249953508378,1.452591664592425,12.483455833016222,26.04072630421751,23.82178964626679,70.7854739085505,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-08-13,2.5,2.5899999141693115,2.25,2.319999933242798,570264,0.0,0.0,2.2549999952316284,1.8239999949932098,1.4576333304246267,2.8824806274331185,23.62938604284498,25.134350108600756,59.973706304842636,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-08-14,2.319999933242798,2.319999933242798,2.0,2.2200000286102295,688296,0.0,0.0,2.236999988555908,1.8438749969005586,1.4613416641950607,-0.7599445700781164,21.32058801796048,26.176858025614813,55.97084262336339,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-08-15,2.259999990463257,2.259999990463257,2.0,2.0799999237060547,459345,0.0,0.0,2.2129999876022337,1.8614999949932098,1.4636333306630454,-6.009944177192854,18.88262119551099,27.18349302348325,50.85350295815937,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-08-16,2.069999933242798,2.180000066757202,2.0,2.1600000858306885,409773,0.0,0.0,2.2049999952316286,1.8794999957084655,1.4670916646718979,-2.0408122221430216,17.318435768363383,28.11060419519179,53.471382945188076,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-08-19,2.1600000858306885,2.259999990463257,2.009999990463257,2.240000009536743,323966,0.0,0.0,2.23199999332428,1.8974999964237214,1.4720083316167196,0.35842366650496144,17.628458367905203,28.905520143332375,55.99565475316579,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-08-20,2.2300000190734863,2.2799999713897705,2.059999942779541,2.259999990463257,191514,0.0,0.0,2.25,1.9169999957084656,1.4773833314577738,0.4444440205891927,17.370892281534285,29.756438622934116,56.6291431532515,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-08-21,2.259999990463257,2.2799999713897705,2.130000114440918,2.190000057220459,168107,0.0,0.0,2.252999997138977,1.936499997973442,1.4826333324114482,-2.7962689746347116,16.3439194163054,30.612198959792476,53.714487408298325,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-08-22,2.180000066757202,2.25,2.119999885559082,2.200000047683716,225995,0.0,0.0,2.2549999952316284,1.9564999997615815,1.4871333330869674,-2.439022069366485,15.25683595739443,31.561841580156795,54.07811233909179,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-08-23,2.190000057220459,2.2799999713897705,2.180000066757202,2.2300000190734863,271976,0.0,0.0,2.2450000047683716,1.9800000011920929,1.4915916661421458,-0.668150809043445,13.383838556400555,32.74410457877972,55.214820125290764,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-08-26,2.259999990463257,2.259999990463257,2.0899999141693115,2.0899999141693115,178527,0.0,0.0,2.1990000009536743,2.0019999980926513,1.4950083325306573,-4.9568024891810385,9.840159992443018,33.912296977220855,49.10601840276268,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-08-27,2.069999933242798,2.2100000381469727,2.009999990463257,2.0999999046325684,270369,0.0,0.0,2.1769999980926515,2.0208749949932097,1.4978833317756652,-3.536981788127963,7.725614077379708,34.91538039865656,49.535497735509026,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-08-28,2.119999885559082,2.1700000762939453,2.0199999809265137,2.069999933242798,137637,0.0,0.0,2.161999988555908,2.040374994277954,1.5008833309014638,-4.255321729884048,5.960913783938744,35.94494337227796,48.2208286559255,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-08-29,2.069999933242798,2.069999933242798,1.7999999523162842,1.9500000476837158,532376,0.0,0.0,2.1490000009536745,2.0562499940395353,1.5025499979654948,-9.260118807894244,4.510638647197284,36.850686953763244,43.27354239420944,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-08-30,1.940000057220459,1.940000057220459,1.75,1.7899999618530273,486024,0.0,0.0,2.111999988555908,2.068624994158745,1.5030499974886575,-15.246213468166264,2.0968031673040266,37.62848858089003,37.717123247637254,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-09-02,1.7899999618530273,1.875,1.6150000095367432,1.815000057220459,284569,0.0,0.0,2.0694999933242797,2.0742499947547914,1.5036333312590917,-12.297653390904935,-0.22899850271294156,37.94918958186998,39.034359945977975,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-09-03,1.815000057220459,2.0,1.815000057220459,1.9950000047683716,461372,0.0,0.0,2.0429999947547914,2.082874995470047,1.5063416649897894,-2.3494855658176834,-1.914421211161405,38.273742529996724,47.623454870895046,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-09-04,1.9700000286102295,1.9950000047683716,1.7999999523162842,1.8200000524520874,290735,0.0,0.0,2.0059999942779543,2.0873749971389772,1.5080499986807505,-9.272180576092985,-3.898437174564136,38.41550339610909,41.50166988852617,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-09-05,1.815000057220459,1.850000023841858,1.7000000476837158,1.7699999809265137,389403,0.0,0.0,1.962999987602234,2.0929999977350233,1.510008332133293,-9.831890366513246,-6.21118061507268,38.60850653572869,39.92262791999726,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-09-06,1.7999999523162842,1.8650000095367432,1.725000023841858,1.809999942779541,115135,0.0,0.0,1.9209999799728394,2.095374995470047,1.5122583319743474,-5.778242496122662,-8.321900178926715,38.559328863766574,41.82942761388507,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-09-09,1.809999942779541,1.815000057220459,1.7200000286102295,1.7649999856948853,73159,0.0,0.0,1.8884999871253967,2.094499996304512,1.5141749987999598,-6.539581798912186,-9.835283339344814,38.326151070020416,40.28051688916046,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-09-10,1.7649999856948853,1.8450000286102295,1.7000000476837158,1.75,153092,0.0,0.0,1.85349999666214,2.0907499969005583,1.5165083318948747,-5.584030043082118,-11.347602563201276,37.86604088671044,39.75211047063792,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-09-11,1.75,1.7699999809265137,1.625,1.6799999475479126,110328,0.0,0.0,1.8144999980926513,2.084999996423721,1.5188416649897893,-7.412513126818471,-12.973621045325789,37.27566503370435,37.293453950937725,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-09-12,1.6799999475479126,1.815000057220459,1.649999976158142,1.7549999952316284,146319,0.0,0.0,1.7949999928474427,2.08162499666214,1.521716665228208,-2.228412132323273,-13.769291023805778,36.7945192576283,41.47041991200345,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-09-13,1.7649999856948853,1.7649999856948853,1.6200000047683716,1.6950000524520874,125436,0.0,0.0,1.7855000019073486,2.074374997615814,1.5241749991973241,-5.06860539672838,-13.925881098667523,36.09821698349872,39.219676226995844,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-09-16,1.6799999475479126,1.7050000429153442,1.590000033378601,1.6050000190734863,99956,0.0,0.0,1.7644999980926515,2.06424999833107,1.525674999753634,-9.039386749310157,-14.521012497554276,35.30076842475658,36.05834557858372,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-09-17,1.5950000286102295,1.649999976158142,1.590000033378601,1.6299999952316284,119385,0.0,0.0,1.727999997138977,2.055749997496605,1.5271749993165333,-5.671296416065143,-15.943086501605078,34.61129198792727,37.56385543293448,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-09-18,1.5950000286102295,1.6399999856948853,1.565000057220459,1.6349999904632568,139326,0.0,0.0,1.709499990940094,2.0466249972581863,1.5282583326101302,-4.3579994660232755,-16.472241215158142,33.918785429602835,37.87888668769956,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-09-19,1.6200000047683716,1.7999999523162842,1.5299999713897705,1.7050000429153442,309985,0.0,0.0,1.702999997138977,2.0372500002384184,1.5299666663010916,0.11744250027758074,-16.406921244831228,33.15649583162196,42.27054442338371,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-09-20,1.7050000429153442,1.75,1.600000023841858,1.6950000524520874,96405,0.0,0.0,1.6915000081062317,2.025874999165535,1.5320499996344248,0.20691955832588438,-16.505213361981053,32.23295582056369,41.81575008374763,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-09-23,1.6950000524520874,1.6950000524520874,1.5700000524520874,1.625,118273,0.0,0.0,1.6775000095367432,2.008000001311302,1.5330499996741613,-3.1296577787347686,-16.459162926231556,30.980724812503702,38.67862590885183,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-09-24,1.6200000047683716,1.6200000047683716,1.5099999904632568,1.565000057220459,241315,0.0,0.0,1.6590000152587892,1.986125001311302,1.5340499997138977,-5.666061312462798,-16.470513479087913,29.469378552310353,36.17355424362642,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-09-25,1.565000057220459,1.6449999809265137,1.5149999856948853,1.625,200921,0.0,0.0,1.6535000205039978,1.9667499989271164,1.536716666817665,-1.7236177895728604,-15.927290128079314,27.98390499661808,40.33508247961601,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-09-26,1.625,1.7000000476837158,1.590000033378601,1.6200000047683716,110270,0.0,0.0,1.6400000214576722,1.9492500007152558,1.5395500004291534,-1.2195131968061879,-15.865075241457365,26.6116722530543,40.100441009555645,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-09-27,1.6150000095367432,1.6150000095367432,1.4500000476837158,1.5,269175,0.0,0.0,1.6205000162124634,1.9307500004768372,1.541841666897138,-7.4359774765139335,-16.068884329289208,25.22362327659451,34.85918464461817,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-09-30,1.4950000047683716,1.7799999713897705,1.399999976158142,1.5950000286102295,380813,0.0,0.0,1.6195000171661378,1.921375000476837,1.5450500001509984,-1.5128118738016005,-15.711403720553326,24.356816950199693,41.39023984272814,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-10-01,1.600000023841858,1.774999976158142,1.4950000047683716,1.600000023841858,262686,0.0,0.0,1.6165000200271606,1.9093750029802323,1.5480500002702078,-1.0207235373263714,-15.338787953960859,23.340654542615308,41.721424060332225,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-10-02,1.6100000143051147,1.6449999809265137,1.5199999809265137,1.5750000476837158,140328,0.0,0.0,1.6105000257492066,1.894750002026558,1.5508416672547658,-2.204282986520049,-15.001977884856979,22.17559290759605,40.489464618574544,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-10-03,1.5750000476837158,1.5750000476837158,1.5,1.534999966621399,110648,0.0,0.0,1.593500018119812,1.8786249995231628,1.5534666667381922,-3.671167294208,-15.177322854519762,20.931143213243462,38.52912037740943,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-10-04,1.534999966621399,1.600000023841858,1.4900000095367432,1.600000023841858,109619,0.0,0.0,1.584000015258789,1.860375002026558,1.5571750005086262,1.01010154223104,-14.855875104035801,19.47115779658011,43.330614088297516,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-10-07,1.600000023841858,1.600000023841858,1.4600000381469727,1.5099999904632568,154716,0.0,0.0,1.5725000143051147,1.8343750029802321,1.5597999999920527,-3.974564278110769,-14.275978916506176,17.603218552992594,38.810309890504065,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-10-08,1.5099999904632568,1.5099999904632568,1.3799999952316284,1.3799999952316284,206272,0.0,0.0,1.5540000081062317,1.810875004529953,1.5617583334445952,-11.196911966985565,-14.185131264230913,15.95103837454218,33.39160540574795,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-10-09,1.3700000047683716,1.4199999570846558,1.2699999809265137,1.340000033378601,363433,0.0,0.0,1.5255000114440918,1.7888750046491624,1.5631333341201146,-12.159946029098348,-14.722939977392342,14.441613239354112,31.91506604682783,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-10-10,1.3350000381469727,1.5449999570846558,1.2799999713897705,1.399999976158142,438116,0.0,0.0,1.5035000085830688,1.7718750059604644,1.564841666817665,-6.883939596546286,-15.146384280753486,13.230305885440288,36.454175838756754,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-10-11,1.3949999809265137,1.399999976158142,1.350000023841858,1.399999976158142,47251,0.0,0.0,1.493500006198883,1.7528750032186509,1.5665499995152155,-6.2604639874564505,-14.797118821564586,11.89397106770263,36.454175838756754,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-10-14,1.3700000047683716,1.399999976158142,1.350000023841858,1.399999976158142,22448,0.0,0.0,1.4740000009536742,1.7318750023841858,1.5682166655858358,-5.020354460492151,-14.88993149479656,10.435951892987466,36.454175838756754,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-10-15,1.399999976158142,1.7200000286102295,1.2649999856948853,1.590000033378601,247001,0.0,0.0,1.4730000019073486,1.7151250034570693,1.5724249988794328,7.942975649677682,-14.117046924374879,9.075154915454139,49.71366027270611,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-10-16,1.5850000381469727,1.690000057220459,1.434999942779541,1.5800000429153442,226788,0.0,0.0,1.4735000014305115,1.6998750030994416,1.577758332590262,7.22769198380996,-13.317155747109208,7.739884365477971,49.132575243675504,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-10-17,1.5800000429153442,1.6399999856948853,1.5,1.6399999856948853,301230,0.0,0.0,1.4840000033378602,1.6858750015497208,1.5835083325703938,10.512128167529982,-11.97449384007055,6.464548804309898,52.70463305794984,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-10-18,1.625,1.6299999952316284,1.2999999523162842,1.5299999713897705,293977,0.0,0.0,1.4769999980926514,1.6683750003576279,1.5884583324193955,3.58835296990938,-11.47074262224943,5.0310836807730785,46.28713666961412,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-10-21,1.5549999475479126,1.5549999475479126,1.4700000286102295,1.5099999904632568,178230,0.0,0.0,1.4769999980926514,1.6538750022649764,1.5932083323597908,2.23425811870146,-10.69458114610205,3.8078303177920763,45.20926802685041,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-10-22,1.5099999904632568,1.559999942779541,1.465000033378601,1.534999966621399,78585,0.0,0.0,1.4924999952316285,1.6397500038146973,1.5980833321809769,2.847569281444097,-8.98002794575441,2.607290295485155,46.874605988701376,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-10-23,1.559999942779541,1.7200000286102295,1.5,1.5499999523162842,182901,0.0,0.0,1.5134999871253967,1.6267500042915344,1.6032499983906745,2.4116263958622284,-6.9617345546256315,1.465773018833553,47.897867669594795,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-10-24,1.559999942779541,1.7100000381469727,1.559999942779541,1.7050000429153442,290731,0.0,0.0,1.5439999938011169,1.6206250041723251,1.609808332224687,10.427464362734048,-4.728114781268705,0.6719229694065474,57.0944037503878,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-10-25,1.715000033378601,1.7999999523162842,1.659999966621399,1.7999999523162842,148048,0.0,0.0,1.5839999914169312,1.6208750039339066,1.6172416652242343,13.636361241778491,-2.2750065506272112,0.22466269499484703,61.571515748498385,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-10-28,1.850000023841858,2.180000066757202,1.850000023841858,2.0199999809265137,723520,0.0,0.0,1.6459999918937682,1.626000002026558,1.6261749982833862,22.721749141836153,1.2300116754171833,-0.010761219242270498,69.50692701675445,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-10-29,2.009999990463257,2.0799999237060547,1.8899999856948853,2.049999952316284,374063,0.0,0.0,1.6919999837875366,1.6273750007152556,1.6354249979058901,21.158390777721277,3.9711180916431235,-0.49222662004936024,70.40440950065627,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-10-30,2.0799999237060547,2.0799999237060547,1.9299999475479126,1.975000023841858,153401,0.0,0.0,1.731499981880188,1.63125,1.6443333312869073,14.06295376897781,6.145592758938719,-0.7956617455821909,65.23511900066414,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-10-31,1.975000023841858,2.0399999618530273,1.8550000190734863,1.8899999856948853,246145,0.0,0.0,1.756499981880188,1.6342500001192093,1.65259999781847,7.6003418839661165,7.480494523607853,-1.110371398008217,59.86995541585516,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-11-01,1.8899999856948853,1.9149999618530273,1.75,1.8700000047683716,228480,0.0,0.0,1.790499985218048,1.6357500016689301,1.6610833312074342,4.440101659126343,9.460491113631605,-1.5251088890338453,58.64773951072003,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-11-04,1.8700000047683716,1.8700000047683716,1.75,1.8049999475479126,191886,0.0,0.0,1.8199999809265137,1.6367500007152558,1.6679583306113879,-0.824177666802227,11.195966404837522,-1.8710497332803704,54.73674837328597,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-11-05,1.75,2.109999895095825,1.75,1.975000023841858,540531,0.0,0.0,1.8639999866485595,1.642375001311302,1.6755416636665663,5.9549376603201924,13.494176735538957,-1.9794591250381706,61.89403735183054,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-11-06,1.975000023841858,1.975000023841858,1.815000057220459,1.9049999713897705,268396,0.0,0.0,1.8994999885559083,1.6480000019073486,1.6830999965469042,0.28954897957349124,15.260921502274313,-2.0854372712000324,57.83845330550844,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-11-07,1.9299999475479126,1.9299999475479126,1.815000057220459,1.8600000143051147,92794,0.0,0.0,1.9149999856948852,1.6506250023841857,1.690399996439616,-2.8720611906330062,16.016659321701326,-2.3529930276387696,55.3285759334928,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-11-08,1.8300000429153442,1.8799999952316284,1.7949999570846558,1.7949999570846558,92797,0.0,0.0,1.9144999861717225,1.653125,1.6973916629950205,-6.241840164544564,15.810963246682647,-2.607922729920374,51.82990899170598,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-11-11,1.7899999618530273,1.9149999618530273,1.7599999904632568,1.9149999618530273,146232,0.0,0.0,1.9039999842643738,1.6608749985694886,1.7055166626969973,0.5777299201451148,14.63836748125468,-2.6174862494110824,57.20953762151958,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-11-12,1.8799999952316284,1.9700000286102295,1.850000023841858,1.9700000286102295,163946,0.0,0.0,1.8959999918937682,1.6693749994039535,1.714166663090388,3.9029555397069564,13.575439465113028,-2.61302851414003,59.445090284185895,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-11-13,1.9700000286102295,1.9700000286102295,1.8849999904632568,1.965000033378601,60316,0.0,0.0,1.8949999928474426,1.6776250004768372,1.7227083300550778,3.6939335512068183,12.957305256467935,-2.617003052211357,59.142587550304185,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-11-14,1.9249999523162842,1.9600000381469727,1.8200000524520874,1.8550000190734863,163862,0.0,0.0,1.8914999961853027,1.6813749998807908,1.730216663579146,-1.9296842286771354,12.497211884285766,-2.8228640219728827,52.77925783379634,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-11-15,1.8550000190734863,1.875,1.7450000047683716,1.8600000143051147,231374,0.0,0.0,1.890499997138977,1.6854999989271164,1.7378499969840049,-1.6133289013499106,12.162562939326657,-3.0123427308306563,53.02665636239411,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-11-18,1.8600000143051147,1.8849999904632568,1.8300000429153442,1.875,68858,0.0,0.0,1.8975000023841857,1.6917499989271163,1.7456416636705399,-1.1857708751470208,12.161962676964865,-3.0872123337218125,53.80852195379187,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-11-19,1.8849999904632568,1.8849999904632568,1.8250000476837158,1.8450000286102295,61073,0.0,0.0,1.884500002861023,1.6987499982118606,1.7529166638851166,-2.096045327186267,10.934510954801281,-3.09008789688852,51.94622349165102,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-11-20,1.840000033378601,1.8849999904632568,1.784999966621399,1.784999966621399,242490,0.0,0.0,1.8725000023841858,1.7027499973773956,1.7584583302338919,-4.672899100207011,9.969167832520451,-3.168021209185349,48.342566341951375,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-11-21,1.8250000476837158,1.8350000381469727,1.7350000143051147,1.7599999904632568,153999,0.0,0.0,1.8625,1.7062499970197678,1.763999996582667,-5.50335621673789,9.157509348169807,-3.2738095053727974,46.883151162432384,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-11-22,1.7599999904632568,1.774999976158142,1.6799999475479126,1.7350000143051147,127717,0.0,0.0,1.856500005722046,1.7121249973773955,1.7686249971389771,-6.544572638968369,8.432503968215036,-3.194572046249433,45.40691500918232,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-11-25,1.7799999713897705,1.8049999475479126,1.6699999570846558,1.7100000381469727,125033,0.0,0.0,1.8360000133514405,1.7149999976158141,1.7722083310286203,-6.862743697613981,7.055394513343445,-3.228081733460844,43.91768040135684,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-11-26,1.715000033378601,1.7649999856948853,1.6649999618530273,1.7050000429153442,111148,0.0,0.0,1.809500014781952,1.7176249980926515,1.7754999985297522,-5.77507438590434,5.348956657671132,-3.2596451976922314,43.6096184306097,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-11-27,1.725000023841858,1.8600000143051147,1.6649999618530273,1.6950000524520874,203448,0.0,0.0,1.7825000166893006,1.7206249982118607,1.7783749987681707,-4.908833852340148,3.5960780845182896,-3.2473466280346854,42.960560716999694,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-11-28,1.7200000286102295,1.7200000286102295,1.5,1.659999966621399,289556,0.0,0.0,1.7630000114440918,1.7237499982118607,1.7815416653951008,-5.84231674158212,2.2770130977779415,-3.243913308669287,40.67853497403738,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-11-29,1.659999966621399,1.9700000286102295,1.659999966621399,1.8350000381469727,355171,0.0,0.0,1.7605000138282776,1.7296249985694885,1.7858333319425583,4.231753691196616,1.7850699015292182,-3.1474568408871986,53.87223984783137,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-12-02,1.840000033378601,2.0399999618530273,1.774999976158142,1.809999942779541,127671,0.0,0.0,1.7540000081062317,1.7371249973773957,1.7900416652361553,3.1926986553307737,0.9714333023998196,-2.9561696180841937,52.08987608441539,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-12-03,1.809999942779541,1.8300000429153442,1.715000033378601,1.7799999713897705,131004,0.0,0.0,1.7475000023841858,1.7471249967813491,1.7939999987681707,1.8597979376963478,0.02146415416913555,-2.612876366722841,49.95405005616707,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-12-04,1.7699999809265137,1.9249999523162842,1.649999976158142,1.6950000524520874,341031,0.0,0.0,1.7385000109672546,1.7559999972581863,1.7962499996026358,-2.502154629896435,-0.9965823643653859,-2.2407795325457744,44.39922604070658,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-12-05,1.690000057220459,1.715000033378601,1.5950000286102295,1.6200000047683716,155308,0.0,0.0,1.724500012397766,1.761499997973442,1.7982916663090387,-6.059727856081392,-2.10048172683755,-2.0459233073748764,40.156162688579755,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-12-06,1.6150000095367432,1.809999942779541,1.5800000429153442,1.6200000047683716,218061,0.0,0.0,1.7130000114440918,1.7669999986886977,1.7997916658719382,-5.429072157292012,-3.0560264450865713,-1.8219701649387288,40.156162688579755,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-12-09,1.6100000143051147,1.6649999618530273,1.5449999570846558,1.6649999618530273,142794,0.0,0.0,1.7085000038146974,1.77362499833107,1.8009999990463257,-2.5460955144597115,-3.671858176201468,-1.5199889355775418,43.887654282948844,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-12-10,1.6649999618530273,1.6699999570846558,1.5700000524520874,1.6349999904632568,261149,0.0,0.0,1.7014999985694885,1.7747499972581864,1.8022916654745738,-3.9083166712983024,-4.127341811627659,-1.5281471220217393,42.007127830844446,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-12-11,1.6349999904632568,1.8350000381469727,1.6050000190734863,1.7100000381469727,84451,0.0,0.0,1.702999997138977,1.777999997138977,1.8047916660706202,0.4110417510132448,-4.218222728947372,-1.4844743266115492,48.005332309279986,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-12-12,1.7100000381469727,1.7949999570846558,1.6649999618530273,1.774999976158142,49432,0.0,0.0,1.7144999980926514,1.7813749969005586,1.8079166660706203,3.5287243005421844,-3.7541224573300944,-1.4680803417642132,52.58273610315063,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-12-13,1.7949999570846558,1.7949999570846558,1.7100000381469727,1.7549999952316284,85128,0.0,0.0,1.706499993801117,1.7869999974966049,1.8117916663487752,2.842074515481298,-4.504756788374918,-1.3683509706241166,51.09228722085634,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-12-16,1.7549999952316284,1.774999976158142,1.7200000286102295,1.7699999809265137,73539,0.0,0.0,1.7024999976158142,1.7934999972581864,1.8164583325386048,3.9647567345213908,-5.073877880205662,-1.263906519029961,52.186915376383716,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-12-17,1.7100000381469727,1.7200000286102295,1.659999966621399,1.715000033378601,110948,0.0,0.0,1.6960000038146972,1.7979999989271165,1.8195416659116745,1.1202847595028553,-5.672969698180403,-1.1839062214475145,47.94924521328232,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-12-18,1.715000033378601,1.7899999618530273,1.6699999570846558,1.7100000381469727,87415,0.0,0.0,1.6975000023841857,1.8020000010728836,1.8230416665474574,0.7363791307941245,-5.799112021447288,-1.1542065033775795,47.57106362374608,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-12-19,1.7000000476837158,1.7000000476837158,1.649999976158142,1.6699999570846558,77560,0.0,0.0,1.7024999976158142,1.8011249989271163,1.8259999990463256,-1.9089597989234393,-5.475744402529003,-1.3622672580613846,44.5442464540449,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-12-20,1.6649999618530273,1.8300000429153442,1.6150000095367432,1.7549999952316284,76298,0.0,0.0,1.71599999666214,1.8,1.8298333326975504,2.2727271937849003,-4.666666852103337,-1.6303852468120654,51.59274643396936,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-12-23,1.7649999856948853,1.7649999856948853,1.6699999570846558,1.7200000286102295,214650,0.0,0.0,1.72150000333786,1.7925000011920929,1.8309166659911473,-0.08713184575789644,-3.9609482737525603,-2.0982202801817866,48.84004361323189,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-12-27,1.7200000286102295,1.850000023841858,1.7200000286102295,1.75,197659,0.0,0.0,1.7330000042915343,1.7850000023841859,1.8317499995231628,0.980957626449367,-2.9131651553611357,-2.552204020807792,51.24141677325745,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2024-12-30,1.7799999713897705,1.7799999713897705,1.6699999570846558,1.6699999570846558,73022,0.0,0.0,1.7289999961853026,1.7773750007152558,1.8319999992847442,-3.4123793655765664,-2.721710641282,-2.9817138968785653,45.15465779795977,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-01-02,1.6699999570846558,1.7400000095367432,1.649999976158142,1.7400000095367432,54183,0.0,0.0,1.7254999995231628,1.7736250013113022,1.833624999721845,0.8403367150152075,-2.713369610405746,-3.2722066082020387,50.67567334224076,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-01-03,1.690000057220459,1.9450000524520874,1.690000057220459,1.8899999856948853,636633,0.0,0.0,1.7389999985694886,1.7741250008344651,1.835083332657814,8.683150503140316,-1.9798493481832085,-3.321829082010179,59.97389782503971,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-01-07,1.875,2.180000066757202,1.7999999523162842,2.180000066757202,539305,0.0,0.0,1.7800000071525575,1.7835000038146973,1.838250000278155,22.471913370636415,-0.19624315417178392,-2.97837598015358,71.25576960403157,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-01-08,2.180000066757202,2.380000114440918,2.109999895095825,2.259999990463257,496921,0.0,0.0,1.834500002861023,1.7906250029802322,1.8412500003973642,23.194330168364065,2.4502617693692037,-2.749490694159213,73.47673117405529,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-01-09,2.2699999809265137,2.299999952316284,2.069999933242798,2.0999999046325684,327660,0.0,0.0,1.8734999895095825,1.7955000013113023,1.842833333214124,12.089667274686011,4.344193157411013,-2.568508559602983,62.99337043201032,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-01-10,2.0999999046325684,2.2300000190734863,1.7999999523162842,1.9900000095367432,500380,0.0,0.0,1.9054999947547913,1.798750001192093,1.8436666667461394,4.434532406956305,5.934676497120304,-2.4362682454588858,56.97483880358865,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-01-13,1.9950000047683716,2.4800000190734863,1.9550000429153442,2.319999933242798,1049777,0.0,0.0,1.9619999885559083,1.8118750005960464,1.846458332737287,18.24668434123633,8.2856150623236,-1.8729549174268338,67.12312102354707,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-01-14,2.319999933242798,2.7699999809265137,2.200000047683716,2.569999933242798,904317,0.0,0.0,2.046999979019165,1.8282499998807906,1.8511249989271163,25.549582783788416,11.964992706284022,-1.2357349751952855,72.42875473858916,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-01-15,2.569999933242798,2.630000114440918,2.2300000190734863,2.299999952316284,786691,0.0,0.0,2.1019999742507935,1.836499997973442,1.8538749982913336,9.419599452472061,14.456845988038546,-0.9372260985182765,60.98256863645396,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-01-16,2.299999952316284,2.3499999046325684,2.1600000858306885,2.2699999809265137,397973,0.0,0.0,2.1619999766349793,1.8441249966621398,1.8561249981323877,4.995374905583012,17.23717104579094,-0.6465082622303024,59.85079007653074,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-01-17,2.2699999809265137,2.390000104904175,2.130000114440918,2.2799999713897705,445395,0.0,0.0,2.215999972820282,1.854749995470047,1.8577916651964188,2.888086613468508,19.47701729249413,-0.16372501736087713,60.11650283629443,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-01-20,2.2200000286102295,2.4000000953674316,2.109999895095825,2.3299999237060547,593731,0.0,0.0,2.259999966621399,1.8664999932050705,1.8592916637659074,3.0973432795798903,21.082238138165106,0.38769223676090886,61.48888842391175,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-01-21,2.569999933242798,2.9600000381469727,2.2899999618530273,2.5299999713897705,986373,0.0,0.0,2.2949999570846558,1.8828749924898147,1.8608749975760779,10.23965223091489,21.888068312483597,1.1822392660653398,66.46037540135193,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-01-22,2.5999999046325684,2.619999885559082,2.450000047683716,2.5199999809265137,197579,0.0,0.0,2.3209999561309815,1.8997499912977218,1.8615416636069615,8.57389179477873,22.17396850969339,2.0525099404290033,66.00159080801308,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-01-23,2.450000047683716,2.5899999141693115,2.390000104904175,2.5899999141693115,206716,0.0,0.0,2.369999957084656,1.9198749899864196,1.8631249954303106,9.282698779255599,23.44553522734417,3.045957447584019,67.68331791506287,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-01-24,2.5999999046325684,2.7799999713897705,2.549999952316284,2.6500000953674316,288747,0.0,0.0,2.4359999656677247,1.942124992609024,1.8658749967813493,8.7848987157538,25.429618327254815,4.086554348989439,69.09446664801652,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-01-27,2.640000104904175,2.640000104904175,2.390000104904175,2.549999952316284,296491,0.0,0.0,2.4589999675750733,1.9624999910593033,1.8684583296378454,3.700690766212164,25.299361975934232,5.033115265657839,64.07275077862181,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-01-28,2.5399999618530273,2.9200000762939453,2.4100000858306885,2.859999895095825,998440,0.0,0.0,2.487999963760376,1.9912499874830245,1.875874995191892,14.95176594670069,24.946640522280784,6.150462722028565,71.08786447893898,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-01-29,2.890000104904175,3.200000047683716,2.859999895095825,3.190000057220459,876380,0.0,0.0,2.5769999742507936,2.0283749878406523,1.885124996304512,23.78735308865813,27.04751289573883,7.598965151751694,76.3759883420446,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-01-30,3.2200000286102295,3.3499999046325684,2.950000047683716,3.319999933242798,627225,0.0,0.0,2.6819999694824217,2.06899998486042,1.894791661699613,23.78821666741103,29.62783900954722,9.194062159031441,78.07710035754768,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-01-31,3.299999952316284,3.380000114440918,3.2100000381469727,3.359999895095825,378935,0.0,0.0,2.7899999618530273,2.1114999830722807,1.9046249936024349,20.430105413486185,32.1335535979268,10.861717669605895,78.58800255329973,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-02-03,3.359999895095825,3.5299999713897705,3.140000104904175,3.440000057220459,396700,0.0,0.0,2.900999975204468,2.151624983549118,1.9138749947150548,18.579803054910446,34.82832730540484,12.422440832895694,79.61139735960603,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-02-04,3.440000057220459,3.5199999809265137,3.259999990463257,3.4200000762939453,407928,0.0,0.0,2.9899999856948853,2.1918749868869782,1.921124995748202,14.381274001883535,36.41288867215225,14.093304274214075,78.59997665331153,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-02-05,3.430000066757202,3.430000066757202,3.2200000286102295,3.240000009536743,222041,0.0,0.0,3.0619999885559084,2.2283749878406525,1.9287916630506516,5.813194697782564,37.40954755209571,15.532176467217212,69.98261131852149,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-02-06,3.240000009536743,3.430000066757202,3.2200000286102295,3.3299999237060547,275763,0.0,0.0,3.1359999895095827,2.2692499846220016,1.93804166217645,6.186222412163027,38.19543949592487,17.08984532734965,71.65589271981962,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-02-07,3.319999933242798,3.3399999141693115,3.200000047683716,3.240000009536743,216722,0.0,0.0,3.1949999809265135,2.309749984741211,1.9477083295583726,1.408451608102363,38.326658817338966,18.588083733508924,67.59787620674174,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-02-10,3.2300000190734863,3.2300000190734863,2.869999885559082,2.9000000953674316,631894,0.0,0.0,3.2299999952316285,2.3417499870061875,1.9538749963045121,-10.216715181156898,37.93103504448078,19.85157655608921,54.9397369269406,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-02-11,2.890000104904175,2.890000104904175,2.5199999809265137,2.7799999713897705,604133,0.0,0.0,3.222000002861023,2.369624987244606,1.9583749959866206,-13.718188425784355,35.97088232123837,20.999552797639737,51.28925046948401,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-02-12,2.7899999618530273,2.990000009536743,2.700000047683716,2.809999942779541,694056,0.0,0.0,3.1839999914169312,2.3989999860525133,1.9629583289225896,-11.746232714999293,32.72196790030471,22.2134953506249,52.145326530004546,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-02-13,2.7799999713897705,2.809999942779541,2.6700000762939453,2.759999990463257,320764,0.0,0.0,3.127999997138977,2.4252499848604203,1.9677083283662795,-11.764706106531689,28.976394873331046,23.25251409968986,50.55073857767665,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-02-14,2.75,2.75,2.640000104904175,2.6700000762939453,167700,0.0,0.0,3.059000015258789,2.4476249873638154,1.971624995271365,-12.71657198510784,24.97829655487574,24.142521688153792,47.721901008145245,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-02-17,2.680000066757202,2.680000066757202,2.5299999713897705,2.559999942779541,228716,0.0,0.0,2.971000003814697,2.467749986052513,1.974374994635582,-13.833728054777557,20.39307144591248,24.988920177648172,44.44797902943983,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-02-18,2.559999942779541,2.6700000762939453,2.5199999809265137,2.5399999618530273,220003,0.0,0.0,2.8829999923706056,2.486999985575676,1.9781249950329463,-11.897330261022285,15.922798918041234,25.725118069915215,43.858825290851485,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-02-19,2.509999990463257,2.640000104904175,2.5,2.549999952316284,438314,0.0,0.0,2.8139999866485597,2.507874983549118,1.9818749954303105,-9.381664377571527,12.206549573145667,26.5405229558689,44.25667966776801,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-02-20,2.549999952316284,2.549999952316284,2.430000066757202,2.5,208256,0.0,0.0,2.730999994277954,2.5276249825954435,1.985458329319954,-8.458439940020131,8.04609121538586,27.30687646621065,42.62996166000139,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-02-21,2.490000009536743,2.559999942779541,2.4100000858306885,2.490000009536743,336910,0.0,0.0,2.655999994277954,2.548124983906746,1.9899583290020624,-6.249999438962306,4.233505461957991,28.04916297843265,42.295120841112904,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-02-24,2.4700000286102295,2.809999942779541,2.359999895095825,2.549999952316284,945738,0.0,0.0,2.620999979972839,2.567999982833862,1.996291662255923,-2.708890812631397,2.063862830734521,28.638516675057208,45.082341786302216,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-02-25,2.509999990463257,2.7200000286102295,2.049999952316284,2.25,1961734,0.0,0.0,2.567999982833862,2.5812499821186066,1.9999166617790858,-12.383176984407143,-0.5133171671295927,29.067877249563907,35.777246800290925,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-02-26,2.2200000286102295,2.5,2.0999999046325684,2.359999895095825,1364867,0.0,0.0,2.522999978065491,2.596499979496002,2.0029583275318146,-6.460566166736389,-2.8307337574013087,29.633250168294374,40.617093054632015,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-02-27,2.4000000953674316,2.5299999713897705,2.299999952316284,2.369999885559082,247347,0.0,0.0,2.4839999675750732,2.613999977707863,2.0075416594743727,-4.589375342354783,-4.9732215471089125,30.209002905188875,41.052007332274115,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-02-28,2.359999895095825,2.4100000858306885,2.2799999713897705,2.359999895095825,173251,0.0,0.0,2.4529999494552612,2.6294999748468397,2.0124583254257837,-3.7912782827447105,-6.712303748999241,30.66108955525855,40.730752749747126,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-03-03,2.3499999046325684,2.369999885559082,2.2100000381469727,2.309999942779541,319495,0.0,0.0,2.4279999494552613,2.639999973773956,2.0166249920924506,-4.859967427190203,-8.030304031239616,30.91179491109507,39.083853622646515,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-03-04,2.299999952316284,2.3399999141693115,2.25,2.319999933242798,343576,0.0,0.0,2.405999946594238,2.643499970436096,2.02124999165535,-3.574397974246663,-8.984302118326784,30.785404148407203,39.609781081352445,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-03-05,2.319999933242798,2.430000066757202,2.259999990463257,2.359999895095825,384682,0.0,0.0,2.3869999408721925,2.6459999680519104,2.0263333241144816,-1.1311288833338495,-9.78836093374574,30.58068663052888,41.77522008353937,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-03-06,2.319999933242798,2.5399999618530273,2.319999933242798,2.5399999618530273,427059,0.0,0.0,2.390999937057495,2.656999969482422,2.0334999909003577,6.231703417729927,-10.0112922649654,30.66142027893502,50.39510821586733,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-03-07,2.5299999713897705,2.5299999713897705,2.319999933242798,2.390000104904175,481861,0.0,0.0,2.380999946594238,2.6669999718666078,2.038791658480962,0.3779990975140659,-10.723660603273306,30.812776321328663,44.484822235574654,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-03-10,2.4000000953674316,2.4700000286102295,2.390000104904175,2.390000104904175,218266,0.0,0.0,2.3649999618530275,2.668749976158142,2.0445833255847297,1.0570885181562177,-11.381733658781496,30.52781673228735,44.48482223557465,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-03-11,2.4100000858306885,2.4700000286102295,2.299999952316284,2.299999952316284,124672,0.0,0.0,2.369999957084656,2.6619999766349793,2.050374991695086,-2.9535867525701973,-10.969196923864708,29.82990854927715,41.128349223710714,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-03-12,2.3299999237060547,2.509999990463257,2.259999990463257,2.450000047683716,249295,0.0,0.0,2.3789999723434447,2.665749979019165,2.05720832546552,2.9844504483256524,-10.756822992875993,29.58094452665313,48.15019661843627,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-03-13,2.450000047683716,2.450000047683716,2.309999942779541,2.390000104904175,126570,0.0,0.0,2.3809999942779543,2.6687499821186065,2.0634999930858613,0.3779970872679417,-10.782201021776487,29.331232908201955,45.797165056676796,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-03-14,2.319999933242798,2.430000066757202,2.319999933242798,2.430000066757202,50324,0.0,0.0,2.388000011444092,2.6724999845027924,2.06954165995121,1.7587962777149118,-10.645462103216087,29.13487252852871,47.634418387701345,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-03-17,2.450000047683716,2.5899999141693115,2.380000114440918,2.5,255308,0.0,0.0,2.407000017166138,2.676749986410141,2.0762499928474427,3.8637300444789737,-10.077518282003318,28.922335731794586,50.77870964672083,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-03-18,2.509999990463257,2.549999952316284,2.4000000953674316,2.490000009536743,231138,0.0,0.0,2.4240000247955322,2.6757499873638153,2.083458326260249,2.7227716198880043,-9.408575679983858,28.42829413183963,50.31392510098538,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-03-19,2.5199999809265137,2.5799999237060547,2.4200000762939453,2.450000047683716,365219,0.0,0.0,2.4330000400543215,2.6739999890327453,2.090833326180776,0.6987261549331827,-9.012713162560622,27.89159018797598,48.40535505629608,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-03-20,2.4800000190734863,2.5299999713897705,2.390000104904175,2.390000104904175,96822,0.0,0.0,2.418000054359436,2.668999993801117,2.0972083270549775,-1.1579796867572447,-9.404269015535418,27.264419055072253,45.610491571304536,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-03-21,2.4000000953674316,2.4200000762939453,2.3299999237060547,2.4000000953674316,224308,0.0,0.0,2.4190000534057616,2.6627499938011168,2.1037083278099695,-0.7854467804405191,-9.154067823220547,26.574105288309063,46.16836819952415,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-03-24,2.4000000953674316,2.450000047683716,2.299999952316284,2.309999942779541,138683,0.0,0.0,2.4110000371932983,2.6567499935626984,2.1104583273331325,-4.189136991110702,-9.250021905141693,25.884977644637214,41.99358148566502,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-03-25,2.3399999141693115,2.440000057220459,2.299999952316284,2.440000057220459,235104,0.0,0.0,2.425000047683716,2.646249997615814,2.1174999942382176,0.6185570821357557,-8.360886164626818,24.970484288847295,49.146680652398665,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-03-26,2.4200000762939453,2.440000057220459,2.2899999618530273,2.3299999237060547,266889,0.0,0.0,2.4130000352859495,2.624749994277954,2.123583326737086,-3.4397061900605825,-8.067433449038077,23.60004720468952,44.18193414204078,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-03-27,2.369999885559082,2.369999885559082,2.119999885559082,2.25,244774,0.0,0.0,2.3990000247955323,2.5979999959468842,2.1292083263397217,-6.210922186556944,-7.659737161732484,22.01718187027066,40.94257510263005,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-03-28,2.2699999809265137,2.359999895095825,2.180000066757202,2.2799999713897705,679808,0.0,0.0,2.3840000152587892,2.5709999978542326,2.1354166597127913,-4.362417919604303,-7.273433790412849,20.398049072073192,42.64094506671033,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-03-31,2.299999952316284,2.799999952316284,2.200000047683716,2.799999952316284,983849,0.0,0.0,2.4140000104904176,2.5549999952316282,2.145416659116745,15.99005551567701,-5.5185904111294555,19.09108584453269,62.676678671009114,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-04-01,2.809999942779541,3.0799999237060547,2.799999952316284,3.0399999618530273,498760,0.0,0.0,2.469000005722046,2.5454999923706056,2.1581666588783266,23.12677014206793,-3.0053029612196527,17.9473319124293,68.1980789325132,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-04-02,3.0399999618530273,3.059999942779541,2.9000000953674316,2.950000047683716,196156,0.0,0.0,2.519000005722046,2.5382499933242797,2.1712499926487605,17.109965898476762,-0.7583960466014781,16.902705902962698,64.35343436268671,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-04-03,2.890000104904175,3.190000057220459,2.880000114440918,2.950000047683716,372444,0.0,0.0,2.575,2.5287499964237212,2.1846666594346362,14.563108647911285,1.8289670248813807,15.749923930185734,64.35343436268671,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-04-04,2.869999885559082,2.940000057220459,2.7699999809265137,2.9200000762939453,246681,0.0,0.0,2.6269999980926513,2.5207499980926515,2.197333326935768,11.153409912981669,4.215015375598324,14.71859854817272,62.98084493381173,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-04-07,2.9000000953674316,3.0999999046325684,2.609999895095825,3.0999999046325684,691671,0.0,0.0,2.705999994277954,2.52574999332428,2.2114999930063886,14.560233229407155,7.136494167280468,14.209812403873862,67.46477353562466,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-04-08,3.0850000381469727,3.0850000381469727,2.9000000953674316,3.0,455349,0.0,0.0,2.761999988555908,2.5312499940395354,2.2248333265384037,8.616944693346234,9.11604918754495,13.772567313070702,62.90611336942687,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-04-09,2.9800000190734863,2.9800000190734863,2.799999952316284,2.865000009536743,155087,0.0,0.0,2.815499997138977,2.5326249957084657,2.235458326339722,1.7581251091481578,11.169241475143114,13.293321815366443,57.27913273748537,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-04-10,3.0,3.134999990463257,2.9100000858306885,2.9549999237060547,380471,0.0,0.0,2.8859999895095827,2.5374999940395355,2.2469166586796443,2.3908501194484457,13.733990001523418,12.93253731674439,59.85713878498716,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-04-11,2.950000047683716,3.065000057220459,2.9000000953674316,3.059999942779541,137479,0.0,0.0,2.9639999866485596,2.5472499907016752,2.2587499916553497,3.2388649312893576,16.360781135269914,12.772551194782523,62.68621799507743,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-04-14,3.065000057220459,3.25,3.059999942779541,3.25,198783,0.0,0.0,3.008999991416931,2.5644999921321867,2.2730833252271014,8.009305725174917,17.33281343920677,12.820324871987266,67.19195804305176,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-04-15,3.25,3.375,3.25,3.3499999046325684,285341,0.0,0.0,3.039999985694885,2.5847499907016753,2.2884166578451794,10.197365802514081,17.61292181568494,12.949273544247378,69.29358900557422,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-04-16,3.384999990463257,3.4100000858306885,3.2850000858306885,3.3499999046325684,177999,0.0,0.0,3.0799999713897703,2.6047499895095827,2.303541657328606,8.766231680221983,18.245512382924197,13.075879536308674,69.29358900557423,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-04-17,3.3499999046325684,3.3499999046325684,3.1549999713897705,3.2699999809265137,185506,0.0,0.0,3.1119999647140504,2.6239999890327455,2.3178749909003575,5.07712140115597,18.59756012656047,13.207140131982548,65.40623027947088,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-04-22,3.2850000858306885,3.434999942779541,3.2699999809265137,3.390000104904175,291394,0.0,0.0,3.158999967575073,2.646499991416931,2.331916658083598,7.312445068064473,19.365198481778584,13.49033346637106,68.28072564057413,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-04-23,3.3949999809265137,3.3949999809265137,3.2899999618530273,3.369999885559082,174578,0.0,0.0,3.1859999656677247,2.666999989748001,2.344999990860621,5.77526434005452,19.460066663470922,13.731343289652,67.2773345370577,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-04-24,3.359999895095825,3.865000009536743,3.3399999141693115,3.825000047683716,628079,0.0,0.0,3.268499970436096,2.706374990940094,2.3600416580835977,17.026161305835018,20.770402526544967,14.674882185669805,75.93967257364933,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-04-25,3.9000000953674316,4.349999904632568,3.8350000381469727,4.349999904632568,781494,0.0,0.0,3.4169999599456786,2.7561249911785124,2.3792083243529003,27.30465190587014,23.978410662884258,15.842104407907462,81.8951202853908,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-04-28,4.355000019073486,4.559999942779541,4.34499979019165,4.505000114440918,477280,0.0,0.0,3.571999979019165,2.8094999969005583,2.4002916584412257,26.119824773289757,27.140059902466536,17.0482756551792,83.2160080847559,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-04-29,4.489999771118164,4.489999771118164,4.144999980926514,4.420000076293945,337883,0.0,0.0,3.7079999923706053,2.8610000014305115,2.421374992529551,19.201728300655763,29.60503287370117,18.15600682493606,79.7786218561728,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-04-30,4.414999961853027,4.414999961853027,4.190000057220459,4.239999771118164,153460,0.0,0.0,3.8069999694824217,2.909249997138977,2.441124990582466,11.373780013310864,30.858467757199016,19.176609487939974,72.91032160744003,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-05-02,4.25,4.505000114440918,4.139999866485596,4.440000057220459,316955,0.0,0.0,3.915999984741211,2.9622500002384187,2.4630833248297375,13.381002924438889,32.1968093316239,20.265927278086966,75.44035834312007,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-05-05,4.394999980926514,4.400000095367432,4.110000133514404,4.195000171661377,388236,0.0,0.0,4.000500011444092,3.0081250071525574,2.4815833260615667,4.8618962544903255,32.989819303782866,21.217973040085113,67.16501465508927,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-05-06,4.204999923706055,4.260000228881836,3.799999952316284,4.150000095367432,571940,0.0,0.0,4.088500022888184,3.0483750104904175,2.500291660428047,1.5042209156159767,34.120638334140935,21.92077663325642,65.7386353360305,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-05-07,4.135000228881836,4.135000228881836,3.7950000762939453,3.8499999046325684,249019,0.0,0.0,4.134500002861023,3.084875005483627,2.5168749928474425,-6.881124634939743,34.02487930666876,22.567668805576364,57.04150707233074,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-05-08,3.7950000762939453,4.465000152587891,3.674999952316284,4.400000095367432,606208,0.0,0.0,4.237500023841858,3.1351250052452087,2.5385833273331326,3.8348099259299966,35.16207541174037,23.498999283933813,65.93852773495102,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-05-09,4.480000019073486,5.179999828338623,4.449999809265137,5.119999885559082,878021,0.0,0.0,4.367000007629395,3.2056250035762788,2.5652916600306828,17.24295572736785,36.22928454692785,24.96142460221997,73.63617759666877,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-05-12,5.139999866485596,5.190000057220459,4.65500020980835,4.744999885559082,597995,0.0,0.0,4.406500005722046,3.2629999995231627,2.58841665883859,7.681830917904866,35.04443782917526,26.06162104470673,65.35220652599594,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-05-13,4.784999847412109,5.190000057220459,4.784999847412109,5.0,362089,0.0,0.0,4.4559999942779545,3.3282499969005586,2.6137083252271016,12.208258671916688,33.88417331713711,27.3382329916775,67.98936044998703,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-05-14,5.010000228881836,5.010000228881836,4.630000114440918,4.684999942779541,376008,0.0,0.0,4.482499980926514,3.384624993801117,2.637291657924652,4.517567489451971,32.437123437194266,28.337151624123347,61.73809340962488,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-05-15,4.704999923706055,4.980000019073486,4.505000114440918,4.650000095367432,367363,0.0,0.0,4.52350001335144,3.4383749961853027,2.6605416586001716,2.796508934290199,31.559240000582456,29.23590145904288,61.06624925465552,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-05-16,4.644999980926514,4.96999979019165,4.644999980926514,4.90500020980835,468054,0.0,0.0,4.570000028610229,3.498750001192093,2.6857916603485745,7.330419673979663,30.61807865818193,30.268853420224296,64.1290394212685,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-05-19,5.019999980926514,5.78000020980835,5.010000228881836,5.449999809265137,1493480,0.0,0.0,4.695499992370605,3.5737499952316285,2.7158333251873654,16.068572422968085,31.388597373506865,31.589444834029916,69.62826026207385,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-05-20,5.5,5.550000190734863,5.210000038146973,5.449999809265137,327967,0.0,0.0,4.825499963760376,3.6502499878406525,2.7463749905427295,12.941660971811622,32.196424349965035,32.91156526004128,69.62826026207385,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-05-21,5.460000038146973,5.460000038146973,4.875,5.139999866485596,665805,0.0,0.0,4.954499959945679,3.7187499821186067,2.774541656176249,3.7440691904244323,33.23025166437927,34.03114614770729,63.233287317512755,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-05-22,6.0,6.880000114440918,5.829999923706055,6.46999979019165,2818832,0.0,0.0,5.161499929428101,3.8227499783039094,2.8139999876419703,25.3511552582455,35.02059927335798,35.84754779999963,74.18708835189734,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-05-23,6.539999961853027,7.380000114440918,6.25,7.380000114440918,1205254,0.0,0.0,5.3874999523162845,3.9462499797344206,2.8612499882777533,36.983762037306086,36.52201406356064,37.920489153405,78.83364062078488,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-05-26,7.340000152587891,7.480000019073486,6.710000038146973,7.0,1021900,0.0,0.0,5.612999963760376,4.062999981641769,2.9053749879201254,24.710494302416077,38.14915060600826,39.844254133624055,72.92991200842849,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-05-27,7.0,7.039999961853027,6.159999847412109,6.320000171661377,793569,0.0,0.0,5.744999980926513,4.1647499859333035,2.9439166555802028,10.00870657343556,37.943453996772924,41.469697453527004,63.73213218326399,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-05-28,6.090000152587891,6.440000057220459,5.900000095367432,6.429999828338623,424058,0.0,0.0,5.9194999694824215,4.268499982357025,2.983666654427846,8.62403685257283,38.67869260746089,43.06222767957171,64.51183319099694,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-05-30,6.639999866485596,6.769999980926514,6.070000171661377,6.21999979019165,511605,0.0,0.0,6.076499938964844,4.353999978303909,3.0202083190282187,2.3615543926303806,39.561322215071094,44.1622404279997,61.781129107256525,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-06-02,6.300000190734863,6.380000114440918,6.019999980926514,6.309999942779541,234768,0.0,0.0,6.216999912261963,4.435749977827072,3.0577083190282184,1.4958988552364494,40.15668023082461,45.067793099271626,62.513479540422566,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-06-03,6.300000190734863,6.300000190734863,5.900000095367432,5.960000038146973,428122,0.0,0.0,6.267999935150146,4.510999977588654,3.0925416529178618,-4.913846525044606,38.949234455565076,45.867072585181,57.869402137443274,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-06-04,6.019999980926514,6.340000152587891,5.860000133514404,6.300000190734863,349138,0.0,0.0,6.352999973297119,4.594749981164933,3.1309166540702185,-0.8342481156150475,38.266499795194676,46.75414547339413,60.907586538379455,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-06-05,6.309999942779541,6.400000095367432,5.96999979019165,6.179999828338623,383138,0.0,0.0,6.456999969482422,4.6762499749660495,3.1689166525999704,-4.289920124717032,38.0807271649181,47.56620282611006,59.282665145890235,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-06-09,6.059999942779541,6.059999942779541,5.860000133514404,5.980000019073486,336001,0.0,0.0,6.4079999923706055,4.748249977827072,3.205249986052513,-6.679150652414137,34.95498388446431,48.13977064156765,56.573677151306185,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-06-10,5.989999771118164,6.0,5.829999923706055,6.0,235620,0.0,0.0,6.269999980926514,4.823249977827072,3.2413749863704044,-4.306219804591067,29.99533529778231,48.80259143444568,56.78633681687465,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-06-11,6.0,6.0,4.735000133514404,5.550000190734863,1437118,0.0,0.0,6.125,4.8903749823570255,3.2739999880393347,-9.387751988002233,25.246019417674994,49.370036659214286,50.76288057320313,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-06-12,5.420000076293945,5.429999828338623,5.130000114440918,5.340000152587891,510148,0.0,0.0,6.026999998092651,4.949999988079071,3.304249988993009,-11.398703264014827,21.75757601226839,49.80706679483458,48.19376024289922,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-06-13,5.190000057220459,5.199999809265137,4.900000095367432,5.170000076293945,372086,0.0,0.0,5.901000022888184,5.002749991416931,3.332541656494141,-12.387729939991729,17.955125341309337,50.11815326203192,46.157223319232614,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-06-16,5.099999904632568,5.789999961853027,4.920000076293945,5.639999866485596,524455,0.0,0.0,5.843000030517578,5.062499988079071,3.364916655421257,-3.474245472731927,15.41728482521265,50.449491220616636,52.17442917133964,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-06-17,5.699999809265137,5.699999809265137,5.400000095367432,5.420000076293945,130957,0.0,0.0,5.754000043869018,5.114249992370605,3.395333322882652,-5.804657021700153,12.509166592418957,50.625859261104466,49.391944194448826,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-06-18,5.440000057220459,5.440000057220459,5.239999771118164,5.329999923706055,191892,0.0,0.0,5.691000032424927,5.163749992847443,3.4254583219687142,-6.343351022000439,10.210603540214054,50.74625079308161,48.258106064019984,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-06-19,5.25,5.570000171661377,5.25,5.349999904632568,136963,0.0,0.0,5.596000003814697,5.215749990940094,3.4557916541894276,-4.395998910193614,7.290418703640089,50.92779058648064,48.540808087919864,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-06-23,5.300000190734863,5.349999904632568,5.010000228881836,5.070000171661377,231571,0.0,0.0,5.485000038146973,5.257749992609024,3.4841249893109003,-7.566086847755021,4.322191923492013,50.90589484417194,44.84654118727589,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-06-24,5.150000095367432,5.449999809265137,5.110000133514404,5.409999847412109,131079,0.0,0.0,5.428000020980835,5.3087499916553496,3.5145833214124043,-0.33161705046332685,2.2462920558122055,51.04920003779919,49.83877554766819,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-06-25,5.420000076293945,5.440000057220459,5.28000020980835,5.380000114440918,112447,0.0,0.0,5.366000032424926,5.347624993324279,3.54508332212766,0.26090350226227726,0.34361121289517305,50.84624273696292,49.41377080359669,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-06-26,5.460000038146973,5.909999847412109,5.460000038146973,5.659999847412109,184887,0.0,0.0,5.376999998092652,5.380374991893769,3.5776666541894278,5.263155094287602,-0.0627278545863775,50.38782290109056,53.40740451181202,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
2025-06-27,5.650000095367432,6.0,5.599999904632568,5.869999885559082,229099,0.0,0.0,5.429999971389771,5.414499986171722,3.612666653593381,8.103129217083517,0.2862680812195877,49.8754384323316,56.20029282534547,,-0.928,0.0,1.0,-0.58267,,8.696296,58.699997,Elicera Therapeutics AB (publ),Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden."
